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Abstract 
Introduction: (1) Ghrelin is a peptide and has been suggested involved in energy 
metabolism. (2) Physical activity plays an important role in the regulation of body fat. 
Generally, the body composition of obese people tend to be resistant to negative energy 
balance. Little is known, however, with respect to the molecular mechanism and basis 
underlying the differences of responsiveness between obese and non-obese humans. 
Methods: This study consists of two parts: ( 1) Genetic association of 3 single nucleotide 
polymorphisms (SNPs) in the ghrelin precursor gene (GHRL) with obesity phenotypes in 
the NL population ( 1182 subjects); (2) A global gene expression study of abdominal 
subcutaneous adipose tissue (ASAT) and comparison between lean and obese young men 
(10 subjects) in response to a 7-day aerobic exercise protocol using whole genome 
mRNA microarrays. Results: No significant association of any of the variant sites and 
body compositions or serum lipids was found in allele, genotype and haplotype analyses. 
In microarray experiment, the discoveries include, and to our knowledge the first time 
reported the differential regulations: 1) 6 inflammatory-related genes (SMPD3, CERK, 
ASAH2, ST3GAL5, ILJRIJ, and AGTRJ) within obese ASAT; 2) the genes in the lipolytic 
pathway (PRKACA, SLC27A6, ADCY6, ADCYAPJ, PPPJCB, DGAT2, and VLDLR); 3) 
the genes in the protein tyrosine phosphatase (PTP) pathway (PTPNJJ, PTPRD, and 
PTPN3) related to insulin sensitivity; 4) PPARA and PPRCJ that may favourably control 
energy metabolism in lean individuals, while not in obese. Conclusion: ( 1) The SNPs 
investigated within GHRL were not significantly associated with the variations of body 
composition and lipids in the NL population; (2) The genome-wide mRNA microarray 
11 
expression study revealed many major differences of ASA T between obese and non-
obese at the molecular level, with respect to the regulation of inflammation, lipolysis and 
insulin sensitivity. 
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Chapter 1: Introduction 
1.1: The prevalence and consequences of obesity 
Obesity, a condition of excessive body fat, is one of the most serious public health 
problems worldwide affecting millions of people (Zimmermann-Belsing and Feldt-
Rasmussen, 2004). Canada, in particular, has recently experienced a major epidemic of 
obesity, with its prevalence more than doubling between 1985 and 1998 (Katzmarzyk, 
2002). Moreover, Newfoundland and Labrador has one of the highest rates of obesity in 
Canada (Canadian Institute for Health Information, 2004). The state of being obese 
increases an individual's risk for adverse health problems, such as type II diabetes, 
cardiovascular disease, hypertension, stroke, dyslipidemia, osteoarthritis, and certain 
types of cancer (Burton et al., 1985;Visscher and Seidell, 2001). 
1.2: Definitions of obesity 
Body composition is most commonly assessed using the body mass index (BMI), 
which is defined as weight, in kilograms, divided by the square of height, in meters 
(kg/m2). According to the WHO (World Health Organization, 1995), overweight is 
defined as a BMI of over 25 kg/m2, and obese as over 30 kg/m2. However, it is the 
amount of body fat, rather than the amount of excess body weight, that determines the 
health risks of obesity (World Health Organization, 1998). BMI is not a direct measure 
of adiposity nor does it indicate body fat distribution. Furthermore, BMI does not 
differentiate people with different body sizes, thus, a person with a small frame may be 
1 
considered as having a healthy body composition when actually they have an unhealthy 
level of body fat. Consequently, obesity is more accurately defined according to body fat 
percentage. According to Bray (2003) obesity classification based on body fat percentage 
differs between ethnic groups and between age groups within these ethnic groups. 
Obesity for white females aged 20-39 years is classified as 2:: 39% body fat, for those aged 
40-59 years, it is classified as 2:: 41%, and for 60-79 year olds, it is 2:: 43%. Obesity for 
white males aged 20-39 years is classified as 2:: 26% body fat, for those aged 40-59 years, 
it is classified as 2:: 29%, and for 60-79 year olds, it is 2:: 31% (Bray, 2003). 
1.3: Etiology of obesity 
The increased prevalence of obesity is largely due to the increased consumption of 
more energy-dense, nutrient-poor foods containing high levels of sugar and saturated fats 
in combination with decreased physical activity (World Health Organization, 2003). It 
has been known, however, for nearly 30 years that genetics plays a role in obesity 
(F einleib et al., 1977). It has also become apparent that obesity aggregates in families 
(Rice et al, 1999), and it is estimated that the heritability of fatness in Caucasian families 
is 46-60% (Katzmarzyk et al., 2000). Animal studies have shown that the genetic 
backgrounds of different strains of rodents have a strong effect on the predisposition to 
obesity (Qiu et al., 2001). Additionally, there are large variations in the extent to which 
an individual alters energy metabolism and gains or loses weight (Poehlman et al., 
1986;Bouchard et al., 1990;Levine et al., 1999). 
Obesity that is caused by a single-gene mutation, such as the leptin and leptin 
receptor genes, are rare in humans and not likely responsible for the common form of 
2 
obesity (Comuzzie et al., 2001). It is widely accepted that the common form of obesity is 
a complex disease that is influenced by both multiple genetic and environmental factors, 
as well as their interactions, which results in a significant degree of variation in 
expression across populations. As of October 2004, more than 600 genes, markers, and 
chromosomal regions have been associated or linked with obesity phenotypes (Perusse et 
al., 2005). To better understand the pathogenesis of polygenic obesity, however, it is 
imperative to identify novel, and confirm suspected, underlying causative genes. 
1.4: Approaches to identify obesity genes 
A common approach employed to identify underlying genes of complex diseases, 
such as obesity, is through genetic association analysis. Association studies offer a 
powerful means of identifying genetic variants that influence susceptibility to complex 
diseases (Risch and Merikangas, 1996). In their simplest form, they compare the 
frequency of alleles or genotypes of a particular variant between disease cases and 
controls (Hirschhorn and Daly, 2005). Association studies have been successful in 
identifying many genetic risk factors for common diseases (Lohmueller et al., 2003 ), such 
as apolipoprotein E (APOE) for the age of onset and risk of Alzheimer's disease 
(Strittmatter and Roses, 1996), peroxisome proliferator-activated receptor-gamma 2 
(PP ARy2) for type 2 diabetes (Deeb et al., 1998), and apolipoprotein A-V (APOA V) for 
hypertriglyceridemia (Pennacchio et al., 2001). This approach, however, has been 
questioned due to non-replication of results as well as limitations in the ability to include 
all possible causative genes and polymorphisms (Taboret al., 2002). Explanations for 
3 
lack of reproducibility usually include small sample size, random error, poorly matched 
control groups, over-interpretation of data, and positive publication bias (Cardon and 
Bell, 2001). A good study design, however, can overcome all of these problems 
(Colhoun et al., 2003). 
Association studies are classified as either genome-wide or candidate-gene 
association studies (Hirschhorn and Daly, 2005). Genome-wide association studies 
employ genotyping a dense set of single nucleotide polymorphisms (SNPs) across the 
genome to determine causal genetic variants. This approach is a powerful method for 
identifying genes involved in common diseases, such as obesity, since no assumptions are 
made about their genomic location or their function. However, the major obstacles facing 
the genome-wide approach are the enormous associated cost and the issue of type one 
errors (false positives) when performing multiple tests. Candidate-gene studies, on the 
other hand, rely on generating hypotheses about, and identifying candidate genes that 
might have a role in, the etiology of the disease (Taboret al., 2002). This approach 
entails genotyping genetic variants, such as SNPs, in or near causative genes in a 
population and determining whether there is an association between those variants and the 
disease phenotype. 
A more novel approach used to identify underlying causative genes in obesity, and 
other complex diseases, is microarray technology (Bell eta!., 2005). A commonly used 
platform for high-density microarrays utilizes robotic "spotting" of DNA molecules. 
These spotted arrays are commonly known as "eDNA microarrays", yet clones, PCR 
products, or oligonucleotides can all be spotted. Microarrays can provide simultaneous 
information on mRNA expression from thousands of genes in any tissue of interest, on a 
4 
single chip. Consequently, a more complete understanding of gene function, regulation, 
and the simultaneous interactions among thousands of genes is obtainable (Quackenbush, 
2001). Through sophisticated analysis using bioinformatic tools, including gene 
ontology, cluster analysis, and systematic pathway analysis between diseased and healthy 
human tissues, we can narrow down the potential disease causing genes of the whole 
human genome to several hundred or even less based on their differential expression. 
In the present study, both the candidate-gene association approach and microarray 
technology were employed to identify underlying causative genes of obesity, in an 
attempt to increase our knowledge of the mechanisms that underlie this condition. 
1.5: Candidate-gene association approach- The ghrelin gene 
Growth hormone (GH), which is secreted from the anterior pituitary, promotes 
protein building in all cells, increases use of fatty acids for energy, and reduces use of 
carbohydrates (Mosby's Medical Encyclopedia, 1997). GH release is stimulated by 
hypothalamic growth hormone releasing hormone (GHRH) and is inhibited by 
somatostatin (SS). Recent studies, however, have indicated that another mechanism 
exists for the regulation of GH release. An endogenous ligand, known as ghrelin, was 
shown to have specificity for the growth hormone secretagogue receptor (GHSR) subtype 
1 a (Howard eta!., 1996;Kojima eta!., 1999), a G-protein-coupled receptor, which 
stimulates the release ofGH (Takaya eta!., 2000;Peino eta!., 2000;Arvat eta!., 2000). 
SNPs and haplotypes within the GHSR gene are linked and associated with obesity in 
humans (Baessler et al., 2005). The ghrelin receptor, as demonstrated by in situ 
5 
hybridization analyses, is expressed in the hypothalamus, pituitary, and hippocampus 
(Guan eta!., 1997). 
The human ghrelin gene (Figure 1.1), also known as the ghrelin precursor gene 
(GHRL), is encoded by 4 exons spanning 4.1 kb of genomic DNA chromosome 3p26-25 
(Wajnrajch et al., 2000). The mature ghrelin product arises following modification of 
preproghrelin, which consists of 117 amino acids. Amino acids 1-23 and 52-117 of 
preproghrelin are cleaved leaving the 28-amino acid ghrelin peptide, which is encoded by 
parts of exons 1 and 2. Furthermore, ghrelin has a post-translational serine-3 residue n-
octanoylation, which is essential for its activity (Figure 1.2). 
The major source of circulating ghrelin is from the stomach (Kojima et al., 1999), 
where ghrelin is produced in X/ A-like cells, a distinct cell type found in the submucosal 
layer (Date et a!., 2000). Ghrelin, however, is also expressed in other tissues such as the 
hypothalamus, pituitary, small and large intestines, lung, placenta, and kidney (Kojima et 
al., 1999;Mori et al., 2000;Korbonits et al., 2001 ;Ariyasu eta!., 2001 ;Kojima et al., 
200la). 
Recent studies have shown that ghrelin specifically stimulates GH release (Kojima 
et al., 1999;Peino et al., 2000) and that ghrelin is more potent for GH release than GHRH, 
on a per mole basis (Takaya et al., 2000). Aside from this role, however, ghrelin has also 
been implicated in food intake and control of energy balance. It has been demonstrated 
that intravenous ghrelin infusion in humans stimulates food intake (Wren eta!., 2001 ), 
and that central or peripheral administration of ghrelin in rodents stimulates food intake, 
reduces fat utilization and increases body weight (Wren et al., 2000;Tschop eta!., 
2000;Shintani et al., 2001;Nakazato et al., 2001). Studies have also demonstrated that 
6 
Exon 1 Exon2 Exon 3 Exon4 
3' 
28 amino acids 
MPSPGTVCSLLLLGMLWLDLAMA SSFLSPEHQRVOORKESKKPPAKLQP ALAGWLRPEDGGQAEGAEDELEVRFNAPFDVGIKLSGVQYQQHSQALGKFLQDILWEEAKEAPADK 
1-23 
'1?-117 
Figure 1.1 Schematic diagram of the 4 exons of the human ghrelin gene showing the 
encoded 117 amino acid sequence of preproghrelin, along with the sequence of mature 
ghrelin peptide highlighted in yellow. 
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Figure 1.2 The structure of the 28-amino acid mature ghrelin peptide, with its Ser3 
residue modified by n-octanoic acid (Kojima et al., 2001b). 
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part of ghrelin's orexigenic effect stems from its stimulatory action on genes encoding the 
appetite stimulators agouti-related protein (AGRP) and neuropeptide Y (NPY), which are 
found mainly in the arcuate nucleus of the hypothalamus (Kamegai eta!., 2000;Nakazato 
eta!., 2001). 
Based on previous literature indicating ghrelin's strong orexigenic action, it would 
seem plausible that elevated levels of ghrelin might be a contributing factor to obesity in 
humans. Moreover, the hypothesis that ghrelin plays a physiological role in meal 
initiation in humans has been demonstrated by the rise of circulating ghrelin levels with 
fasting and its decrease after food intake in humans (Cummings eta!., 2001). Yet, 
contrary to this hypothesis, it has been reported that plasma ghrelin levels are decreased 
in obese Caucasians as compared with lean Caucasians (Tschop eta!., 2001), and that 
weight loss increases circulating levels of ghrelin in humans (Hansen eta!., 2002). Thus, 
recent evident suggests that the regulation of the entire ghrelin system is altered in obesity 
(Marzullo eta!., 2004). It should be noted, however, that current methods can only 
measure total ghrelin levels, that is, ghrelin's active, n-octanoylated form cannot be 
distinguished from its inactive form. 
Since the gene encoding ghrelin and its overall genomic structure (Wajnrajch et 
a!., 2000) has previously been characterized, it is possible to perform genomic screening 
of the GHRL gene within certain populations. Genetic polymorphisms within the GHRL 
gene, even if they do not lead to an amino acid change or they are not in a coding region, 
may still affect gene function by altering the stability, splicing, or localization of the 
mRNA (Cartegni eta!., 2002). Thus, in effect, the expression of the ghrelin protein may 
be altered, which may, in tum, alter GH secretion and/or control of food intake and 
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energy balance, and thus have importance in the etiology of obesity. The GHRL gene 
appears in the 2004 human obesity gene map (Perusse et al., 2005), however, the roles of 
genetic variations within this gene on body compositions and serum lipids are still not 
clear in humans. Our study investigated three SNPs within the GHRL gene to determine 
their relationship with body fat percentage (%BF), trunk fat percentage (% TF), lower 
body (legs) fat percentage (%LF), BMI, and serum lipids in a healthy population. 
1.6: Microarray technology approach- Global gene expression responses to acute 
aerobic exercise 
When studying the underlying causative genes of obesity, it is of importance to 
study human tissue that plays a major role in energy homeostasis. Adipose tissue is an 
active participant in whole body energy homeostasis (Rajala and Scherer, 2003), and 
functional adipocytes are critical in physiological and pathophysiological conditions 
(Nadler and Attie, 2001). 
1.6.1: Tissue of interest: adipose 
Adipose tissue is the largest energy reservoir in the body (Fruhbeck et al., 2001). 
It is found in mammals in two forms: white adipose tissue (W AT) and brown adipose 
tissue (BAT). W AT makes up the majority of adipose tissue in the body (Albright and 
Stem, 1998), and it is the main focus here. 
The primary role of adipocytes is to synthesize and store lipids when nutrients are 
abundant, and release fatty acids when nutrients are needed (Spiegelman and Flier, 1996). 
Excessive adipose tissue, however, accumulates when caloric intake continues to exceed 
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expenditure. Under these conditions, adipocytes swell, to as much as 6 times their 
minimum size, and then begin to multiply, from 40 billion (average adult) to 100 billion 
(Underwood and Adler, 2004). It is also known that excessive adipose tissue increases 
one's risk for numerous medical conditions such as coronary artery disease, hypertension, 
dyslipidemias, type II diabetes, and cancer (Rajala and Scherer, 2003). 
Adipose tissue is a heterogeneous organ, whereby it is composed of mature 
adipocytes as well as several other cell types in the stromavascular fraction, which 
include preadipocytes, endothelial cells, and macrophages (Clement et al., 2004). The 
biological function ofWAT is not simply the storage oflipids, as once believed. The 
tissue is now recognized as a highly dynamic organ, with involvement in metabolic 
regulation and physiological homeostasis (Trayhum and Beattie, 2001 ). The paradigm 
shift occurred upon the discovery ofleptin, a cytokine-like hormone secreted from 
adipocytes that established adipocytes as endocrine cells (Zhang et al., 1994). Since then, 
numerous other adipokines, or protein signals and factors synthesized and secreted by 
adipocytes, have been discovered. The classification of these adipokines by functional 
role include appetite and energy balance, immunity, insulin sensitivity, angiogenesis, 
inflammation and acute-phase response, blood pressure, lipid metabolism, and 
haemostasis (Trayhum and Wood, 2004). 
There are various approaches to studying obesity. One of these approaches is to 
introduce an intervention that influences energy metabolism within the human body, thus 
influencing the expression and regulation of genes, and possibly providing insight into the 
mechanisms that underlie obesity. Exercise, for instance, exerts an immediate and 
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substantial increase in energy expenditure, which causes the body to establish adaptive 
mechanisms to meet the fuel demands of the muscle (Pagano et al., 1999). 
1.6.2: Exercise as an intervention 
During physical activity, to meet the fuel demand of the body, excess non-
esterified fatty acids (NEF A) are released through an increase in lipolysis of the major 
triglyceride (TG) store within the body, the adipose tissue (Stich and Berlan, 2004). Once 
NEF A are released, they initially enter the interstitial space, and then ultimately into 
circulation where they are delivered into the skeletal muscle, and then the mitochondria 
before being oxidized. The entry of fatty acids into the skeletal muscle, however, is a 
complex process involving a series of protein carriers, such as plasma membrane fatty 
acid-binding protein, fatty acid translocase, and fatty acid transport protein, to facilitate 
fatty acid entry into the cells and solubility within the aqueous cytosol (Horowitz, 2003). 
The different adipose tissue depots in the body have varying lipolytic activity 
(Martin and Jensen, 1991). During exercise, for instance, most fatty acids delivered to the 
systemic circulation are derived from subcutaneous adipose tissue (Horowitz, 2003). 
However, it is the subcutaneous adipose tissue of the upper body, rather than lower body, 
that has the greater lipolytic rate during exercise (Arner et al., 1990). Consequently, the 
majority of the plasma fatty acids available to the working muscle most likely are derived 
from abdominal subcutaneous fat (Horowitz, 2003). Furthermore, the lipolytic response 
to exercise differs between obese and lean men. It was demonstrated that the lipolytic 
response to exercise decreases with increasing adiposity, which limits the availability of 
plasma fatty acids as a fuel during exercise for obese men, in comparison with lean men 
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(Mittendorfer et al., 2004). However, the underlying molecular and genetic mechanisms 
responsible for this difference between lean and obese men remain unknown. The 
responses, especially the possible differences between obese and non-obese individuals, 
to all known and possibly unknown adipokines to exercise are of great interest due to 
their interactions with other tissues, organs, as well as the central nervous system. 
Exercise is also of great importance when studying obesity, since it has been 
shown that regular aerobic physical activity contributes to the cure of metabolic 
complications associated with this condition (Richterova et al., 2004). Physical activity 
may also modify the effect of genes on the regulation of body weight (Meirhaeghe et al., 
1999), however, little is known about the global genetic differences between lean or 
obese individuals. The present study investigated the differential global mRNA 
expression profiles of abdominal subcutaneous adipose tissue of lean and obese males, in 
response to short-term aerobic exercise, using long oligonucleotide whole human genome 
microarrays. We decided to use long oligonucleotide micro arrays because these arrays 
are known to have a superior ability to distinguish closely related sequences, and in fact a 
single long oligonucleotide is suitable to detect single-copy genes in human cells (Hughes 
et al., 2001). 
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Chapter 2: Materials and Methods 
2a: Candidate-gene association study 
2a.l: Subjects 
Subjects were recruited from the province ofNewfoundland and Labrador (NL), 
Canada, by means of poster distribution and person-to-person contact. Subjects who met 
the following criteria were eligible to participate in the study: ( 1) 19 to 60 years of age, 
(2) at least third generation Newfoundlander, (3) healthy, without any serious metabolic, 
cardiovascular or endocrine diseases, and (4) not pregnant at the time of the study. One 
thousand one hundred and eighty two subjects participated in the study. All subjects 
provided written consent and completed questionnaires pertaining to their demographic 
background, health status, and family history. The Research Ethics Board of the Faculty 
of Medicine, Memorial University ofNewfoundland, approved the study. 
2a.2: Study Design 
This study was a candidate-gene association study on a large NL based cohort 
utilizing a combination of case-control and haplotype analyses. All measurements and 
blood samplings were performed in the morning following a 12-hour fast. 
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2a.2.1: Blood samples 
For plasma isolation, blood was collected in evacuated tubes containing K3EDTA 
as an anti-coagulant. Tubes were immediately centrifuged at 4 °C for 15 minutes at 
1300g. Plasma was removed and stored at -80 °C until further analysis. For serum 
isolation, blood was collected in tubes containing a clot activator. Tubes were allowed to 
sit at room temperature for 20 minutes, followed by centrifugation at 25 °C for 10 minutes 
at 3500 rpm. Serum was removed and stored at -80 °C until further analysis. 
2a.2.2: Body composition measurements 
Subjects were weighed, and their heights were measured, wearing standardized 
light gowns, without shoes, on a platform manual scale balance (Health o meter Inc., 
Bridgeview, IL, USA). Whole-body composition measurements, including %BF, %TF, 
%LF, lean body mass, and bone mineral densities were determined using DXA Lunar 
Prodigy (GE Medical Systems, Madison, WI, USA). Measurements were performed on 
subjects, following the removal of all accessories containing metal, while lying in a 
supine position. Software version 4.0 was used for analysis. Classification for lean and 
obese were as follows: obese for females aged 20-39 years was classified as 2: 39% body 
fat (lean as< 33%) and aged 40-59 years was classified as 2:41% (lean as< 35%); obese 
for males aged 20-39 years was classified as 2:26% body fat (lean as< 21 %) and aged 
40-59 years was classified as:::::_ 29% (lean as< 23%) (Bray, 2003). 
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2a.2.3: Biochemical measurements 
Serum concentrations of glucose, total cholesterol, high-density lipoprotein-
cholesterol (HDL-C), and triglycerides (TGs) were measured using Synchron reagents 
performed on an Lx20 (Beckman Coulter, Inc., CA, USA) by Dr. Edward Randell in the 
discipline of Laboratory Medicine. Serum insulin levels were measured on an Immulite 
immunoassay analyzer (DPC, CA, USA). Low-density lipoprotein-cholesterol (LDL-C) 
was determined using the following equation: [total cholesterol- HDL-C- (TGs/ 2.2)], 
and risk factor was determined using the equation: (total cholesterol/HDL-C). 
2a.3: Genomic DNA extraction and genotyping 
Genomic DNA was extracted from whole blood (5ml) using the WizardCf~! 
Genomic DNA purification kit (Promega, Madison, WI, USA) according to the 
manufacturer's protocol. This kit is designed for the isolation of DNA from white blood 
cells. Briefly, the protocol was comprised of four main steps. Firstly, red blood cells 
were lysed in the Cell Lysis Solution and removed. Secondly, white blood cells and their 
nuclei were lysed in the Nuclei Lysis Solution. Thirdly, cellular proteins were removed 
by a salt precipitation step, leaving genomic DNA in solution. Finally, the genomic DNA 
was concentrated and desalted by an isopropanol precipitation. 
The three SNPs in the GHRL gene that were investigated were an NG 
polymorphism (public ID, dbSNP: rs35684; public location: chromosome 3- 10,301,686) 
found in exon 1 (mis-sense mutation), a CIT intronic polymorphism (public ID, dbSNP: 
rs2075356; public location: chromosome 3- 10,303,809) located intron 2, and an A/G 
intergenic polymorphism (public ID, dbSNP: rs26311; public location: chromosome 3 -
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10,307,926) found near the 3' untranslated region (UTR) (Figure 2.1). Since the ghrclin 
gene is small, three SNPs were sufficient to cover any signal across the gene. The SNPs 
were not chosen at random, they were chosen based on the following priority hierarchy: 
I) minor allele frequency 2: 0.05; 2) located in exon region; 3) located in exon-intron 
splice region; 4) located in intron; 5) located in the intergenic region. 
Genotyping was performed using the TaqMan® validated SNP Genotyping 
Assays (Applied Biosystems, CA, USA) according to the manufacturer's protocol. Each 
assay required polymerase chain reaction (PCR) amplification and allelic discrimination 
plate read and analysis. PCR amplification required four components: l) puritied 
genomic DNA (20ng). 2) 20X SNP Genotyping Assay Mix (0.75f.!l), which contained 
sequence-specific forward and reverse primers to amplity the desired SNP and two 
TaqMan® minor groove binder (MGB) probes. Each probe had a reporter dye attached 
to its 5' end and a nont1uorescent quencher (NFQ) to its 3' end (Figure 2.2). One 
probe was labelled with VIC dye and detected the Allele 1 sequence and the other probe 
was labelled with FAM dye and detected the Allele 2 sequence. 3) 2X TaqMan® 
Universal PCR Master Mix, No AmpErase® Uracil-N-Glycosylase (UNG) (7.5f.!l), which 
contained AmpliTaq Gold® DNA polymerase and other components required for the 
PCR reaction, such as deoxynucleotides and magnesium chloride. 4) DNAse, RNAse 
Free, distilled water (2.75f.!l). During the PCR reaction, which was performed on an 
EppendorfMastercycler [five steps: 1) 2 minutes at 50°C, 2) 10 minutes at 95 °C, 3) 15 
seconds at 95 °C, 4) 1 minute at 60 °C, 5) 40 cycles of steps 3-4] each probe bound to a 
complementary sequence between the forward and reverse primers, and the proximity of 
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Figure 2.1 Approximate locations ofthe 3 SNPs investigated within the GHRL gene. 
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Figure 2.2 Illustration of the TaqMan minor groove binder probe with a reporter dye 
attached to its 5' end and a nonfluorescent quencher (NFQ) attached to its 3' end (adapted 
from ABI Assays-on-Demand Gene Expression Products Protocol). 
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the reporter dye to the quencher resulted in suppression of the reporter fluorescence. The 
AmpliTaq Gold® DNA polymerase only cleaved probes that were hybridized to the 
target, thereby separating the reporter dye from the quencher, resulting in an increase in 
fluorescence by the reporter. Following PCR amplification, allelic discrimination and 
analysis was performed using an ABI Prism 700(il\l sequence detection system (SDS). 
Briefly, the SDS software calculated the fluorescence measurements from the plate read 
and created a plot of the signals. If there was a substantial increase in the VIC dye 
fluorescence only, it indicated that the sample was homozygous for allele I. If there was 
a substantial increase in the F AM dye fluorescence only, it indicated that the sample was 
homozygous for allele 2, And if there was a substantial increase in both fluorescent 
signals, it indicated heterozygosity for allele I and allele 2 (Figure 2.3). 
To evaluate the quality of genotyping, 5% of the samples were randomly selected 
and re-genotyped. A total of 3,723 SNP genotyping assays (3 SNPs x l, 182 subjects+ 
5% verification) were completed. 
2a.4: Statistical analysis 
All statistical analyses were performed using SPSS software (version 11.5 tor 
Windows), with significance set at p<0.05. Hardy-Weinberg equilibrium was tested using 
chi-square analysis. Chi-square analysis was also used to assess the allele differences 
between obese and non-obese subjects for each of the SNPs investigated. One-way 
genotype groups of SNPs and haplotype groups (combinations of the 3 SNPs ANOV A, 
corrected with Bonferroni t-test, was used to assess differences among investigated) with 
body composition (%BF, %TF, %LF, and BMI) in males and females. Analyses were 
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Figure 2.3 An example of an allelic discrimination showing 4 distinct groups: grey 
squares refer to non-template controls; blue diamonds refer to homozygosity for allele Y; 
green triangles refer to heterozygosity; red circles refer to homozygosity for allele X. 
21 
2.40 
repeated after adjusting 0/cJBF, %TF, %LF, and BMI t()r and age. One-way ANOVA, 
corrected with Bonferroni t-test, was also used to assess differences among genotype 
groups and haplotype groups of SNPs with serum lipid parameters in males and females. 
Due to the skewed distributions, the serum lipid parameters were transformed using log 10 
prior to data analysis. Similarly, analyses were repeated after adjusting serum lipid 
parameters for age and %BF. 
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2b: Genome-wide expression study of adipose tissue in response to short-term 
aerobic exercise using microarray technology 
2b.l: Subjects 
Subjects were recruited from NL, Canada, by means of poster distribution and 
person-to-person contact. Subjects who met the following criteria were eligible to 
participate in the study: (1) male, (2) 20 to 27 years of age, (3) at least third generation 
Newfoundlander, (4) healthy, without any serious metabolic, cardiovascular or endocrine 
diseases, (5) not on medication for lipid metabolism, and (6) either classified, according 
to percent body fat, as lean(< 21 %) or as obese (2:: 26%) (Bray, 2003). All subjects 
provided written consent, and the Research Ethics Board of the Faculty of Medicine, 
Memorial University of Newfoundland, approved the study. 
2b.2: Study Design 
This study employed a longitudinal design. All measurements (except V02 max), 
blood samplings, and adipose tissue samplings were performed twice: prior to exercise 
and the day following the exercise week (81h day). 
2b.2.1: Blood samples 
Refer to section 2a.2.1 
2b.2.2: Body composition measurements 
Refer to section 2a.3 .1. 
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2b.2.3: Biochemical measurements 
Refer to section 2a.3.2. 
2b.2.4: Maximum oxygen consumption (V02 max) measurements 
V02 max is the maximum volume of oxygen in millimetres consumed during 
exercise per kilogram of body weight per minute (mllkg/min). The rational behind the 
determination ofV02 max is that an individual's ability to undergo exercise tor periods of 
time depends on their capacity to transport oxygen from the air into the mitochondria 
(Astrand, 1976). Oxygen consumption is linearly related to energy expenditure, which 
provides a good indication of one's aerobic capacity. In our study, V02 max was 
determined using the SensorMedics MMC Horizon System (Version 11.20) using a 
standard five-stage treadmill protocol. The five stages of the protocol were as follows: 1) 
0-2 minutes at a pace of 5 km/h, with a 0 vertical incline; 2) 2-5 minutes at a pace of 8 
km/h, with a 0 vertical incline; 3) 5-7 minutes at a pace of 10.5 km/h, with a 0 vertical 
incline; 4) 7-9 minutes at a pace of 10.5 km/h, with a 2.0 vertical incline; 5) every 2 
minutes thereafter, vertical grade was increased by 1.0, while pace remained at 10.5 km/h. 
Test was terminated after subjects were exhausted or when they reached their theoretical 
maximum heart rate (220 minus their age). 
2b.3: Exercise protocol 
Subjects trained for 50 minutes, after reaching a heart rate that corresponded to 
60% of their V02 max, for 7 consecutive days using a treadmill. Subjects were not 
restricted to a particular diet; they were to maintain their regular diet. 
24 
2b.4: Adipose tissue isolation from sub,jects 
The "superwet liposuction technique", performed by surgeons, was used to obtain 
subcutaneous adipose tissue from the sub-umbilicus region of subjects be tore and the day 
after the exercise period, in the morning following a 12-hour fast. Briefly, the protocol 
entailed 5 steps: 1) anaesthetizing the sub-umbilicus region, using a combination of 10 cc 
ofXylocaine with adrenalin (1:1000), and 50 ml of0.25% Marcaine in 250 cc ofN/S; 2) 
inserting a cannula, fitted with a syringe to create negative pressure, into the 
subcutaneous fat; 3) removal of -4 grams of fat; 4) draining of t1uid from fat; 5) 
immediately flash freezing fat sample in liquid nitrogen. All samples were stored in 
liquid nitrogen until further analysis. 
2b.S: Total RNA isolation from adipose tissue 
Total RNA was extracted from adipose tissue (500 mg) using the RNeasy@ Lipid 
Tissue Midi Kit (Qiagen, CA, USA) according to the manufacturer's protocol. This kit is 
designed for the optimal lysis of adipose tissue and the purification of high-quality total 
RNA molecules that are greater than 200 nucleotides in length. Thus, since RNAs less 
than 200 nucleotides are excluded, such as 5.8S rRNA, 5S rRNA, and tRNAs, this 
protocol allows for the enrichment ofmRNA. Briefly, the protocol comprised six main 
steps. First, the adipose tissue was homogenized, using a rotor-stator homogenizer 
(Brinkmann Instruments, NY, USA), in QlAzol Lysis Reagent, which is a monophasic 
solution of phenol and guanidine thiocyanate that is designed to facilitate lysis of fatty 
tissues and inhibit RNases. Second, chloroform was used to separate the homogenate into 
aqueous and organic phases. RNA resided in the upper, aqueous phase, while DNA 
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remained in the interphase, and proteins remained in either the interphase or the organic 
phase. Third, the aqueous phase was extracted, and ethanol was added to allow 
appropriate binding conditions. Fourth, the sample was loaded onto the RNeasy Midi 
Spin Column. Total RNA adhered to the membrane, while phenol and other 
contaminants were washed away. Fifth, an on column DNase digestion was performed to 
remove possible DNA contamination. Lastly, high-quality RNA was eluted off the 
membrane using RNase-free water. RNA concentration and purity were determined 
using the Eppendorf BioPhotometer. 
2b.6: Reference RNA 
Universal Human Reference RNA (Stratagene, CA, USA) was used to serve as a 
reference for the microarray experiments. It contained equal, pooled quantities of total 
RNA from 10 different human cell lines, since RNA species differ in abundance between 
cell lines. The 10 human cell lines were as follows: 1) Adenocarcinoma, mammary 
gland; 2) Hepatoblastoma, liver; 3) Adenocarcinoma, cervix; 4) Embryonal carcinoma, 
testis; 5) Glioblastoma, brain; 6) Melanoma; 7) Liposarcoma; 8) Histiocytic lymphoma; 
macrophage; histocyte; 9) Lymphoblastic leukemia, T lymphoblast; 1 0) Plasmacytoma; 
myeloma; B lymphocyte. 
2b.7: Assessment of total RNA integrity and purity 
RNA integrity and purity was assessed prior to microarray assays using the RNA 
6000 nanoassay on an Agilent Bioanalyzer 2100 Automated Analysis System (Agilent 
Technologies, CA, USA). Briefly, this technology uses electrokinetic forces to drive the 
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RNA sample through micro-channels, comprised of a sieving polymer and t1uorescence 
dye, to perform the electrophoretic separations (Figure 2.4). The components were then 
detected by their fluorescence and translated into electropherograms, as well as gel-like 
images. Refer to Appendix 1 for the electropherograms and gel-like images of all RNA 
samples used. 
2b.8: Microarray assays 
Agilent's in situ synthesized 60-mer oligonucleotide microarrays, containing 
44,290 genes and transcripts probes, printed on one single 1" x 3" glass slide, were used 
. . . .... 
(Agilent Technologies, CA, USA). The protocol comprised 3 major components: ( l) 
linear amplification (fluorescent cRNA synthesis), (2) hybridization and washing, and (3) 
scanning and quantifying the arrays. 
2b.8.1: Linear amplification: Fluorescent cRNA synthesis 
Agilent's Low RNA Input Fluorescent Linear Amplification kit was used to 
generate 1 00-fold fluorescent complimentary RNA. This procedure involved labelling 
the total RNA sample (300 ng) with either cyanine 3 (cy3) or cyanine 5 (cy5) (Perkin-
Elmer, MA, USA) and the reference RNA sample with the opposite dye. To control for 
the differences between cy3 and cy5 signals, 2 arrays were competed per sample allowing 
tor a dye swap. Briefly, a primer, containing poly dT and a T7 polymerase promoter, was 
annealed to the poly A RNA. Reverse transcription was then used to synthesize the first 
and second strands of eDNA. Next, eRN A was synthesized using T7 RNA polymerase, 
which also incorporated cy3 or cy5 labelled CTP (Figure 2.5). 
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Figure 2.4 A schematic diagram showing the electrophoretic separation of an RNA 
sample within the micro-channels of the polymer chip (adapted from Agilent 
Technologies Lab-on-a-Chip Products Protocol). 
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Figure 2.5 A schematic overview of Agilent's microarray protocol, including linear 
amplification (fluorescent cRNA synthesis), hybridization and washing, and scanning of 
the arrays (adapted from Agilent Technologies Low RNA Input Fluorescent Linear 
Amplification Kit Protocol). 
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2b.8.2: Hybridization and washing 
Labelled sample (0.75 !lg) and reference RNA (0.75 !lg), along with control 
targets, were combined and then added to the gasket slide to which the microarray was 
placed on, creating a "sandwich slide" pair. The "sandwich slide" pair was then 
hybridized at 60°C for 17 hours at 4 rotations per minute in an Agilent hybridization oven 
(Figure 2.5). Following hybridization, each "sandwich slide" pair was disassembled and 
washed. The wash solution was a stabilization and drying solution that contained an 
ozone scavenging compound that was dissolved in acetonitrile. 
2b.9.3: Scanning and quantifying the microarrays 
Each microarray was scanned using ScanArray Express Microarray Scanner 
(Packard BioScience). One laser was set at 550 nm to excite cy3 and the other was set at 
650 nm to excite cy5, while the laser power was set to 80% to avoid overexposure of 
features (Figure 2.5). The microarray images were quantified to obtain raw intensity 
measurements using the ImaGene software, version 6.0 (BioDiscovery, Inc.), using 
default parameters. 
2b.9: Statistical analysis 
Raw intensity measurements for each micro array underwent further data 
processing for subsequent data analysis using GeneSight Lite version 6.0 (BioDiscovefio,y, • 
Inc., CA, USA). The following parameters were used: (1) correction for background-
background pixel intensity was automatically averaged over the local background and 
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subtracted from the original intensity value; (2) ratio of sample-to-reference- a ratio of 
the intensity value of the experimental sample with intensity value of Universal Human 
Reference RNA was taken; (3) omit multiple flagged spots- spots were automatically 
flagged and omitted if any spot had a mean signal that was not at least twice that of the 
background mean, if any spot was low-expressed or missing, or if any spot had poor 
quality (such as abnormal shape or donut shape); ( 4) log2 shift- all remaining values 
were transformed into log (base 2) scale; (5) normalization- all remaining values were 
normalized by dividing by the Z-score to eliminate differences in intensities between 
equal experiments due to external conditions. A mean value was calculated for each pair 
of processed intensity values (two arrays per sample), and was used in subsequent 
analyses. 
The following criteria were used to determine any differentially expressed genes 
in pre-exercise samples when compared to post-exercise samples (pre/post) of lean and 
obese subjects: (1) 3 of the 5 samples must be in the same direction by l.5 fold; (2) 
average of 5 samples must be 1.5 fold in that particular direction. These criteria ensured 
that a gene or transcript was not considered significant based on an extreme outlier. A 
fold change of 1.5 was chosen based on previous microarray literature. Only genes that 
met the above criteria were used for further analysis. Student paired t-tests were then 
performed on remaining genes, where p::: 0.01 was taken to be statistically significant. 
To help decipher which of the remaining genes were of interest, gene ontology 
analysis was completed. There are three categories of gene ontology: (1) biological 
process -refers to a biological objective to which the gene or gene product contributes; 
(2) molecular function- refers to the biochemical activity of a gene product; (3) cellular 
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component- refers to the place in the cell where a gene product is active (Ashhumer et 
a!., 2000). The Gene Ontology Tree Machine (GOTM), which is a web-based software 
(http://genereg.oml.gov/~gotm) tor interpreting microarray data using gene ontology 
hierarchies, was used to statistically identify gene ontology terms with enriched, that is 
over-represented, genes from our list of differentially expressed genes. The software was 
able to identify over-represented genes by comparing our list of differentially expressed 
genes, with defined HUGO names, with the list of all genes, with defined HUGO names, 
present on each ofthe whole human genome microarrays. This type of analysis was 
completed separately for up- and down-regulated genes of lean and obese subjects. 
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Chapter 3: Results 
3.la: Candidate-gene association study 
The physical and biochemical characteristics of the subjects are shown in Table 
3.1. There were 1182 eligible subjects (946 females and 236 males). On average, the 
mean age of males was about 3 years less than females. Males were also taller, heavier 
and had significantly larger BMI than females. However, when DXA was used to 
evaluate adiposity percentages, males had about 12% less body fat, 8% less trunk fat, and 
3% less lower body fat than females. The mean levels of fasting serum glucose, insulin, 
and triglycerides were significantly higher in males than females, while total cholesterol 
and HDL-C were significantly lower. Furthermore, risk factor tor cardiovascular disease, 
as calculated by total cholesterol divided by HDL-C, was significantly higher in males 
than females. 
The minor allele frequencies (MAFs) of the 3 SNPs investigated are presented in 
Table 3.2. The frequencies for alleles A and G of the SNP located in ex on 1 were 0. 73 
and 0.27, frequencies for alleles C and T of the intron 2 SNP were 0.11 and 0.89, and 
frequencies for alleles A and G of the SNP located in the 3' intergenic region were 0.88 
and 0.12, respectively. All SNPs investigated were in Hardy-Weinberg equilibrium 
according to Chi-Square analysis. 
The genotype distributions of the 3 SNPs investigated in lean and obese males and 
females, based on %BF, are presented in Table 3.3. In males, the MAFs of the lean and 
obese groups for the SNP located in exon 1 were 0.19 and 0.26, the SNP located in 
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Table 3.1 Physical and biochemical characteristics of subjects in candidate-gene 
association study 
Age (yr) 
Weight (kg) 
Height (em) 
BMI (kg/m2) 
%BF 1 
%TF2 
%LF3 
Total Cholesterol (mmol!L) 
LDL-C4 (mmol/L) 
HDL-C5 (mmol/L) 
Glucose (mmol/L) 
Insulin (pmol/L) 
TGs6 (mmol/L) 
Risk factor7 
Females (n = 946) 
43.0 ± 9.9 (19-62)a 
69.2± 13.8 (45.4-156.8)a 
162.1 ± 5.8 (135.0-185)a 
26.3±5.1 (17.0-54.3)a 
37.3 ± 7.1 (4.6-60)a 
38.4 ± 8.2 (3.9-64.3) a 
35.6 ± 8.7 (5.6-57.2) a 
5.24 ± 1.0 (2.25-9.98) h 
3.11 ± 0.91 (1.02-7.61) 
1.58 ± 0.36 (0. 79-3.25) a 
5.00 ± 0.83 (3.0-16.3) a 
73.7 ± 46.9 (15.4-720) h 
1.18 ± 0.74 (0.27-5.88)a 
3.46 ± 0.93 (1.56-8.41)a 
Males (n = 236) 
39.8 ± 12.7 (19-61) 
85.0 ± 14.3 (53.9-149.4) 
175.3 ± 6.7 (157-198) 
27.7 ± 4.6 (18.6-50.4) 
25.6 ± 7.5 (6.0-48.0) 
30.3 ± 8.7 (4.7-53.1) 
32.5 ± 10.9 (6.8-50.7). 
5.08 ± 1.09 (2.82-9.22) 
3.14 ± 0.92 (1.31-5.69) 
1.26 ± 0.25 (0.65-2.21) 
5.26 ± 1.02 (2.2-14.4) 
78.9 ± 52.0 (17.1-363) 
1.50 ± 1.02 (0.31-5.05) 
4.17 ± 1.08 (2.27-7.72) 
Values are expressed as mean± standard deviation (min.- max.); %BF 1 =body fat 
percentage; %TF2 =trunk fat percentage; %LF3 =lower body fat percentage; LDL-C4 = 
low-density lipoprotein-cholesterol; HDL-C5 =high-density lipoprotein-cholesterol; TGs6 
= triglycerides; risk factor7 =total cholesterol/HDL-C. ap value< 0.001, bp value< 0.05 
in the comparison between males and females using Student's t-test. 
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Table 3.2 Minor allele frequencies of SNPs in the GHRL gene 
SNPs ,;Reported for Caucasians 
Exon 1 (A/G; rs35684) 0.18 
Intron 2 (CIT; rs2075356) 0.08 
Intergenic (A/G; rs26311) 0.07 
N L population 
0.27 
0.89 
0.12 
All SNPs are in Hardy-Weinberg Equilibrium; c,MyScience SNP genotyping search 
website (http://myscience.appliedbiosystems.com). 
35 
Table 3.3 Genotype distributions (percentages in parentheses) of three SNPs within 
GHRL in lean and obese (based on %BF) males and females 
Exon I SNP Intron 2 SNP Intergenic SNP 
AA AG GG cc CT TT AA AG GG 
Males* 
Lean 47 26 1 1 12 62 60 14 1 
(n=74-75) (62.7) (34.7) ( 1.3) ( 1.3) (16.0) (82.7) (80.0) (18.7) ( 1.3) 
Obese 54 32 8 0 16 78 74 20 0 
(n=94) (57.4) (34.0) (8.5) (0.0) (17.0) (83.0) (78.7) (21.3) (0.0) 
7 2.069 0.070 0.000 x-
p 0.15 0.80 0.99 
Females(jl 
Lean 174 115 21 5 64 242 240 68 3 
(n=310-311 (56.1) (37.1) (6.8) (1.4) (19.6) (79.1) (79.5) (18.9) (1.4) 
Obese 177 125 28 8 69 252 246 78 6 
(n=329-330 (53.6) (37.9) (8.5) (2.4) (21.0) (76.6) (74.5) (23.6) (1.8) 
x2 0.727 0.306 0.868 
p 0.39 0.58 0.35 
*Males: lean= <21% (20-39 yrs) and <23% (40-59 yrs); obese= 2::26% (20-39 yrs) and 
2::29% (40-59 yrs); <JlFemales: lean= <33% (20-39 yrs) and <35% (40-59 yrs); obese= 
2::39% (20-39 yrs) and 2::41% (40-59 yrs); Significance assessed using x2 test between lean 
and obese groups for each SNP. 
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intron 2 were 0.92 and 0.914, and the SNP located in the 3' intergenic region were 0.11 
and 0.11, respectively. According to chi-squared analysis, there was no signi ticant 
difference of allele frequencies between lean and obese groups, based on 1YoBF, t()r any 
SNP investigated. The MAFs of the lean and obese females for the SNP located in exon 
l were 0.25 and 0.27, the SNP located in intron 2 were 0.88 and 0.87, and the SNP 
located in the 3' intergenic region were 0.12 and 0.14, respectively. According to chi-
squared analysis, there was no significant difference of allele frequencies between lean 
and obese groups, based on %BF, tor any SNP investigated. Similarly, there was no 
significant difference of allele frequencies between lean and obese groups, based % TF 
(Table 3.4), %LF (Table 3.5), or BMI (Table 3.6), for males or females tor any SNP 
investigated. 
The genotype effect of the 3 SNPs investigated in males and females on body 
composition are presented in Table 3.7. Using one-way ANOVA, corrected by 
Bonferroni t-test, there was no significant difference among the 3 genotype groups for 
%BF, %TF, %LF, or BMI for the 3 SNPs investigated in males or females. Although 
statistically not significant, a trend appeared to exist toward higher body fat and the GG 
genotype of Ex on 1 in males. Furthermore, because of possible confounding factors on 
body composition, all analyses were repeated after adjusting for age using linear 
regression. Similar results were obtained for all SNPs investigated in males and females. 
The genotype effect of the 3 SNPs investigated in males and females on serum 
lipid parameters are presented in Table 3.8. Using one-way ANOV A, corrected by 
Bonferroni t-test, there was no significant difference among the 3 genotype groups for 
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Table 3.4 Genotype distributions (percentages in parentheses) of three SNPs within 
GHRL in lean and obese (based on (Yo TF) males and females 
Exon 1 SNP Intron 2 SNP Intergcnic SNP 
AA AG GG cc CT TT AA AG GG 
Males* 
Lean 25 15 1 1 8 32 30 10 1 
(n=4l) (61.0) (36.6) (2.4) (2.4) (19.5) (78.0) (73.2) (24.4) (2.4) 
Obese 85 54 12 0 22 130 126 26 0 
(n=lSl-152 (56.3) (35.8) (7.9) (0.0) (14.5) (85.5) (82.9) (17.1) (0.0) 
x2 0.900 2.088 2.691 
p 0.34 0.15 0.10 
Females!p 
Lean 156 101 20 4 55 218 216 58 3 
(n=277) (56.3) (36.5) (7.2) (1.4) (19.9) (78.7) (78.0) (20.9) ( 1.1) 
Obese 224 166 32 8 91 322 313 101 8 
(n=42l-422 (53.1) (39.3) (7.6) ( 1.9) (21.6) (76.5) (74.2) (23.9) (1.9) 
x2 0.556 0.558 1.584 
p 0.46 0.46 0.21 
*Males: lean= <21% (20-39 yrs) and <23% (40-59 yrs); obese= ::::26% (20-39 yrs) and 
;::::29% (40-59 yrs); <pFemales: lean= <33% (20-39 yrs) and <35% (40-59 yrs); obese= 
;::::39% (20-39 yrs) and ;::::41% (40-59 yrs); Significance assessed using x2 test between lean 
and obese groups for each SNP. 
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Table 3.5 Genotype distributions (percentages in parentheses) of three SNPs within 
GHRL in lean and obese (based on <X,LF) males and females 
Exon 1 SNP Intron 2 SNP Intergenic SNP 
AA AG GG cc CT TT AA AG GG 
Males* 
Lean 37 14 3 1 10 43 41 11 2 
(n=54) (68.5) (25.9) (5.5) (1.9) ( 18.5) (79.6) (75.9) (20.4) (3.7) 
Obese 86 63 11 0 20 141 133 28 0 
(n=160-16l (53.8) (39.4) (6.9) (0.0) (12.4) (87.6) (82.6) (17.4) (0.0) 
x2 2.822 2.819 2.424 
p 0.09 0.09 0.12 
Females<il 
Lean 191 139 32 6 77 279 274 84 5 
(n=362-363 (52.8) (38.4) (8.8) ( 1.7) (21.3) (77.1) (75.5) (23.1) ( 1.4) 
Obese 146 121 24 7 50 233 221 62 7 
(n=290-291 (50.2) ( 41.6) (8.2) (2.4) (17.2) (80.3) (76.2) (21.4) (2.4) 
x2 0.158 0.492 0.007 
p 0.69 0.48 0.93 
*Males: lean= <21% (20-39 yrs) and <23% (40-59 yrs); obese= :::_26% (20-39 yrs) and 
::::29% (40-59 yrs); <JlFemales: lean= <33% (20-39 yrs) and <35% (40-59 yrs); obese= 
:::_39% (20-39 yrs) and :::_41% (40-59 yrs); Significance assessed using x2 test between lean 
and obese groups for each SNP. 
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Table 3.6 Genotype distributions (percentages in parentheses) of three SNPs within 
GHRL in lean and obese (based on BMI) males and females 
Exon 1 SNP Intron 2 SNP Intergenic SNP 
AA AG GG cc CT TT AA AG GG 
Males* 
Lean 39 20 3 1 13 48 44 16 2 
(n=62) (62.9) (32.3) (4.8) (1.6) (21.0) (77.4) (71.0) (25.8) (3.2) 
Obese 30 23 4 0 10 47 46 11 0 
(n=57) (52.6) (40.4) (7.0) (0.0) (17.5) (82.5) (80.7) (19.3) (0.0) 
xz 1.264 0.698 2.201 
p 0.26 0.40 0.14 
Females* 
Lean 238 161 33 8 83 342 339 86 8 
(n=432-433 (55.1) (37.3) (7.6) (1.8) (19.2) (79.0) (78.3) (19.9) ( 1.8) 
Obese 87 68 14 2 36 131 124 43 2 
(n=l69) (51.5) (40.2) (8.3) (1.2) (21.3) (77.5) (73.4) (25.4) (1.2) 
xz 0.561 0.039 1.014 
p 0.45 0.84 0.31 
*Males and Females: lean= ::;:24.9; obese= 2::30%; Significance assessed using x2 test 
between lean and obese groups for each SNP. 
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Table 3.7 Genotype effect of three SNPs within GHRL on %BF, %TF, (Yc,LF, and BMI in 
males and females 
Exon 1 SNP [ntron 2 SNP Intergenic SNP 
AA AG GG p CC* CT TT p AA AG GG* p 
Males 
n 137 82 14 1 37 196 189 43 2 
%BF 25.3 25.8 28.0 ns 25.1 25.8 ns 25.8 24.9 ns 
%TF 30.2 30.3 33.5 ns 29.8 30.6 ns 30.7 29.5 ns 
%LF 31.2 34.3 34.7 ns 29.7 33.1 ns 33.2 29.3 ns 
BMI 27.4 28.1 28.2 ns 27.0 27.8 ns 27.8 27.3 ns 
Females 
n 495 372 74 17 193 731 715 212 15 
%BF 37.2 37.5 37.3 ns 38.3 37.3 37.3 ns 37.2 37.6 38.5 ns 
%TF 38.3 38.6 38.6 ns 39.7 38.5 38.3 ns 38.2 38.9 40.4 ns 
%LF 35.6 35.7 35.1 ns 35.6 35.5 37.6 ns 35.6 35.6 38.0 ns 
BMI 26.2 26.5 26.3 ns 25.7 26.6 26.3 ns 26.2 26.8 25.7 ns 
%BF, %TF, %LF, and BMI are expressed as mean values. Significance was calculated 
using one-way ANOVA, corrected by Bonferroni t-test; ns =not significant; *where n < 
5, genotype group was combined with heterozygous group. 
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Table 3.8 Genotype effect of three SNPs within GHRL on serum lipid parameters (log10 
transtormed) in males and females 
Exon l SNP lntron 2 SNP lntergenic SNP 
AA AG GG p CC* CT TT p AA AG GG* p 
Males 
n 137 82 14 l 37 196 189 43 2 
Total Chol 0.699 0.690 0.711 ns 0.695 0.696 ns 0.696 0.698 ns 
LDL-C 0.488 0.464 0.497 ns 0.467 0.482 ns 0.483 0.465 ns 
HDL-C 0.096 0.088 0.076 ns 0.096 0.092 ns 0.089 0.103 ns 
Glucose 0.717 0.715 0.700 ns 0.705 0.717 ns 0.717 0.708 ns 
Insulin 1.807 1.850 1.890 ns 1.831 1.826 ns 1.825 . 1.834 ns 
TGs 0.076 0.103 0.151 ns 0.113 0.085 ns 0.084 0.110 ns 
Risk factor 0.606 0.603 0.634 ns 0.111 0.112 ns 0.608 0.597 ns 
Females 
n 495 372 74 17 193 731 715 212 15 
Total Chol 0.710 0.711 0.716 ns 0.717 0.714 0.710 ns 0.711 0.714 0.708 ns 
LDL-C 0.473 0.485 0.479 ns 0.491 0.480 0.477 ns 0.477 0.480 0.479 ns 
HDL-C 0.189 0.187 0.193 ns 0.188 0.186 0.189 ns 0.190 0.180 0.21 ns 
Glucose 0.695 0.695 0.696 ns 0.706 0.699 0.694 ns 0.693 0.703 0.701 ns 
Insulin 1.780 1.783 1.756 ns 1. 738 1.801 1.782 ns 0.178 0.181 0.17f ns 
TGs 0.017 -0.001 0.006 ns 0.009 0.014 0.007 ns 0.007 0.016 -0.023 ns 
Risk factor 0.522 0.527 0.522 ns 0.527 0.531 0.52~ ns 0.521 0.534 0.527 ns 
Serum lipid parameters are expressed as mean values. Significance was calculated using 
one-way ANOV A, corrected by Bonferroni t-test; ns = not significant; *where n < 5, 
genotype group was combined with heterozygous group. 
42 
total cholesterol, LDL-C, HDL-C, glucose, insulin, TGs, or risk factor f()f the 3 SNPs 
investigated in males or females. However, in males tor the Exon I SNP, the calculated 
antiloglO mean values tor HDL-C indicated about 1.25 mmol/L tor AA, 1.22 mmol/L tor 
AG, and 1.19 mmol/L for GG. The calculated antilog l 0 mean values tor TG were 1.19 
mmol!L tor AA, 1.27 mmol/L for AG, and 1.42 mmol/L for GG. These values match 
well with the expected trend if there were an association of the G allele and obesity, that 
is, a trend with the number of G alleles with the greatest difference in the GG genotype 
group. Obese individuals, as expected, showed lower HDL-C and higher TG levels. 
Once again, all analyses were repeated after adjusting for age and %BF, possible 
confounding factors, using linear regression. Similar results were obtained for all SNPs 
investigated in males and females. 
The most common haplotypes (n >50), or the combinations of the 3 SNPs 
investigated within GHRL, in the NL cohort are presented in Table 3.9. The effect of the 
haplotypes on body compositions in males and females are presented in Table 3.10. 
Using one-way ANOV A, corrected by Bonferroni t-test, there was no significant 
difference among the 5 common haplotype groups on %BF, %TF, %LF, or BMI in males 
or females. Furthermore, similar results were obtained after all analyses were repeated 
upon adjusting for age in both males and females. 
The haplotype effect of the most common haplotypes on serum lipid parameters in 
males and females are presented in Table 3.11. Using one-way ANOVA, corrected by 
Bonferroni t-test, there was no significant difference among the among the 5 common 
haplotype groups for total cholesterol, LDL-C, HDL-C, glucose, insulin, TGs, or risk 
factor in males or females. Also, similar results were obtained after all analyses were 
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Table 3.9 Common haplotypes within the GHRL gene in the NL population 
Haplotype* n Males Females 
2-0-2 423 104 319 
2-1-1 146 21 125 
1-0-2 371 66 305 
1-l-1 50 11 39 
0-0-2 74 13 61 
*Order ofhaplotype: SNP in Exon 1 - SNP in intronic region.,- SNP in intergenic region; 
0 = homozygous for minor allele; 1 = heterozygous; 2 = homozygous for major allele. 
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Table 3.10 Haplotype effect of three SNPs within GHRL on %BF, %TF, %LF, and BMI 
in males and females 
Haplotype 
0-0-2 1-0-2 1-1-1 2-0-2 2-1-1 p 
Males 
n 13 66 11 104 21 
%BF 27.8 25.7 26.1 25.7 24.9 ns 
%TF 33.4 30.3 30.5 30.6 30.1 ns 
%LF 38.5 34.7 36.5 36.0 30.7 ns 
BMI 28.7 28.1 27.9 27.6 26.9 ns 
Females 
n 61 305 39 319 125 
%BF 37.2 37.8 35.0 36.6 38.2 ns 
%TF 38.4 38.9 36.5 37.6 39.5 ns 
%LF 34.8 35.3 34.0 34.7 35.0 ns 
BMI 26.3 26.5 26.1 25.9 26.8 ns 
Significance was calculated using one-way ANOV A, corrected by Bonferroni t-test; ns = 
not significant. 
45 
Table 3.11 Haplotype etTect of three SNPs within GHRL on serum lipid parameters 
(log 10 transformed) in males and females 
Haplotype 
0-0-2 1-0-2 1-1-1 2-0-2 2-1-1 
Males 
n 13 66 11 104 21 
Total chol. 0.718 0.699 0.646 0.691 0.718 
LDL-C 0.517 0.481 0.371 0.481 0.501 
HDL-C 0.083 0.090 0.056 0.091 0.112 
Glucose 0.710 0.717 0.709 0.719 0.703 
Insulin 1.901 1.847 1.827 1.800 1.841 
TGs 0.125 0.107 0.155 0.067 0.123 
Risk Factor 0.634 0.609 0.597 0.604 0.607 
Females 
n 61 305 39 319 125 
Total chol. 0.721 0.714 0.699 0.706 0.722 
LDL-C 0.491 0.489 0.464 0.465 0.492 
HDL-C 0.201 0.190 0.165 0.189 0.191 
Glucose 0.696 0.692 0.719 0.693 0.695 
Insulin 1.762 1.778 1.831 1.787 1.807 
TGs -0.004 0.000 0.006 0.013 0.011 
Risk Factor 0.522 0.527 0.527 0.515 0.535 
p 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
ns 
Significance was calculated using one-way ANOV A, corrected by Bonferroni t-test; ns = 
not significant. 
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repeated upon adjusting for the confounding factors age and %BF in both males and 
females. 
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3.1b: Genome-wide expression study of adipose tissue in response to short-term 
aerobic exercise using microarray technology 
The physical and biochemical characteristics of lean and obese subjects prior to 
exercise are presented in Table 3.12. On average, the mean age oflean males was 0.8 
years younger than obese males, while the average height for lean males was about 5 em 
greater than obese males. Age and height was not significantly different between lean 
and obese groups. Lean males had significantly less body mass (-22kg), BMI (-9kg/m2), 
body fat (-20%), trunk fat (-23%), and lower body (legs) fat (-17%). The mean levels of 
fasting serum total cholesterol, LDL-C, triglycerides, and risk factor for cardiovascular 
disease, as calculated by total cholesterol divided by HDL-C, were also significantly 
lower in lean males. 
The change in the physical and biochemical characteristics of lean and obese 
subjects following 7 days of aerobic exercise are presented in Table 3.13. According to 
paired t-test analyses (before and after exercise values), we report that obese individuals 
significantly decreased their % TF (p < 0.05). As well, in obese individuals, we observed 
a decrease in %BF and TG levels, although not quite significant (p = 0.07 for both). In 
lean individuals, in response to 7 days of aerobic exercise at the same intensity level, we 
did not observe the decreases in %TF, %BF, or TG levels as we did with the obese 
subjects. However, we did observe a decrease in %LF in lean subjects, although not quite 
significant (p = 0.08). All other post-exercise values of physical characteristics and 
biochemical measurements for both lean and obese subjects did not differ significantly 
from the pre-exercise values. 
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Table 3.12 Physical and biochemical characteristics of subjects in the microarray 
exercise study {pre-exercise values) 
Age (yr) 
Weight (kg) 
Height (em) 
BMI (kglm2) 
%BF 1 
%TF2 
%LF3 
Total Cholesterol (mmol/L) 
LDL-C4 (mmol/L) 
HDL-C5 (mmol/L) 
TGs6 (mmol/L) 
Risk factor7 
Lean (n = 5) 
22.8 ± 1.6 (21-25) 
70.4 ± 7.8 (64.2-82.0)b 
180.6 ± 6.1 (174-190) 
21.6 ± 2.8 (17.9-25.6)b 
12.0 ± 5.0 (7.6-19.8t 
12.9 ± 5.8 (7.1-21.7t 
13.0 ± 5.1 (9.0-20.9)a 
3.21 ± 0.32 (2.87-3.62)a 
1.75 ± 0.35 (1.29-2.13)b 
1.21 ± 0.07 (1.13-1.29) 
0.54 ± 0.09 (0.43-0.66)a 
2.66 ± 0.27 (2.24-2.86)h 
Obese (n = 5) 
23.6 ± 2.6 (22-28) 
92.0 ± 21.4 (7 4.6-123 .0) 
174.7 ± 6.0 (165-182) 
30.7 ± 9.9 (22.5-45.0) 
32.2 ± 6.9 (26.6-42.2) 
35.8 ± 4.7 (32.7-42.6) 
30.1 ± 6.4 (22.3-37.9) 
4.62 ± 0.63 (3.88-5.61) 
2.54 ± 0.59 (1.59-3.15) 
1.18 ± 0.24 (0.93-1.46) 
0.93 ± 0.10 (0.79-1.07) 
3.82 ± 0.71 (3.22-4.83) 
Values are expressed as mean± standard deviation (min.- max.); %BF 1 =body fat 
percentage; %TF2 =trunk fat percentage; %LF3 =lower body fat percentage; LDL-C4 = 
low-density lipoprotein-cholesterol; HDL-C5 =high-density lipoprotein-cholesterol; TGs6 
= triglycerides; risk factor7 =total cholesterol/HDL-C. ap value< 0.01, bp value< 0.05 in 
the comparison between lean and obese males using Student's t-test. 
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Table 3.13 The change in the physical and biochemical characteristics of subjects in the 
microarray exercise study (post-exercise values- pre-exercise values) 
Lean (n = 5) p Obese (n = 5) 
Weight (kg) -0.18 ± 0.63 ( -1.0-0.6) 0.56 -0.90 ± 1.0 (-2.6- -0.1) 
BMI (kg/m-) -0.05 ± 0.19 ( -0.3-0.2) 0.58 -0.30 ± 0.32 (-.9- -0.03) 
%BF 1 -0.80 ± 0.62 (-0.7-0.7) 0.79 -1.08 ± 0.96 ( -2.6-0.0) 
p 
0.11 
0.11 
0.07 
%TFL 0.22 ± 0. 73 ( -0.5-1.3) 0.54 -1.08 ± 0.84 ( -2.1-0.0) <0.05 
%LFj 
-0.62 ± 0.61 (-1.3-0.3) 0.08 -0.44 ± 0.66 ( -1.3-0.4) 0.21 
Total Chol. (mmol/L) 0.06 ± 0.19 (-0.1-0.4) 0.50 0.06 ± 0.57 ( -0.6-0. 7) 0.82 
LDL-C4 (mmol/L) -0.06 ± 0.22 (-0.2-0.3) 0.60 -0.05 ± 0.67 (-0.9-0.71) 0.87 
HDL-C' (mmol/L) 0.08 ± 0.10 ( -0.02-0.2) 0.15 0.10 ± 0.13 ( -0.0 1-0.28) 0.23 
TGs6 (mmol/L) 0.08 ± 0.23 ( -0.2-0.4) 0.50 -0.23 ± 0.21 (-0.41-0.04) 0.07 
Risk factor 1 -0.11 ± 0.17 ( -0.4-0.04) 0.22 -0.11 ± 0.62 ( -0.6-0.8) 0.74 
Values are expressed as mean± standard deviation (min.- max.); Statistical significance 
assessed using paired t-test between pre- and post-exercise values for lean and obese 
separately. %BF1 =body fat percentage; %TF2 =trunk fat percentage; %LF3 =lower 
body fat percentage; LDL-C4 =low-density lipoprotein-cholesterol; HDL-C5 =high-
density lipoprotein-cholesterol; TGs6 = triglycerides; risk factor7 =total cholesterol/HDL-
C. 
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Upon data processing of raw intensity measurements tor each microarray, the 
number of genes and transcripts of interest tor both lean and obese samples greatly 
decreased. After introducing our 5 parameters ( ( 1) correction tor background, (2) ratio of 
sample-to-reference, (3) omit multiple t1agged spots, (4) log2 shift, and (5) 
normalization), the average number of genes and transcripts remaining for the 10 lean 
samples (5 pre and 5 post exercise) was 21,198, while 21,867 remained for the 10 obese 
samples. Subsequently, after introducing our criteria to determine any differentially 
expressed genes in pre-exercise samples when compared to post-exercise samples (3 of 
the 5 samples must be in the same direction by 1.5 fold and the average of 5 samples must 
be 1.5 told in that particular direction), 6,627 genes remained as differentially expressed 
for lean samples, while 8,156 remained for obese samples. Finally, comparing pre-
exercise sample intensity values to post-exercise values of the remaining genes using 
student-paired t-tests, 235 genes were statistically significant (46 up-regulated and 189 
down-regulated) in lean subjects, while 279 were significant (90 up-regulated and 189 
down-regulated) in obese subjects. In lean subjects, of the 235 differentially expressed 
genes, 182 (77%) had defined HUGO names (Table 3.14), while 199 (71 %) had defined 
HUGO names in obese subjects (Table 3.15). The false discovery rate (FDR), which 
provides the expected percent of false positives, was calculated after the consideration of 
duplication of genes and transcripts on the arrays, as well as some function associations 
between genes. The following formula was used: ((#of comparison x level of 
significance )/2/# of significant genes). The FDR, using p :::: 0.01 as the level of 
significance, was 14.6% for obese samples and 14.1% for lean samples. It should be 
pointed out, however, that the calculated FDR for lean and obese is the maximum 
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Table 3.14 Significantly down- and up-regulated genes, classified by biological process, 
of lean subjects in response to short-term exercise. 
Gene symbol Gene name Fold change* 
Regulation of transcription 
ZNF582 
ZNF444 
ZNF136 
ZNF277 
ZNF295 
ZNF419 
IRX5 
CNOT7 
HNRPD 
CRSP9 
KIAA0543 
MLL5 
RELA 
MED28 
FOXP2 
Apoptosis 
BCAP31 
HD 
BCL2L2 
Metabolism 
SLC6A6 
VNN3 
zinc finger protein 582 
zinc finger protein 444 
zinc finger protein 136 (clone pHZ-20) 
zinc finger protein (C2H2 type) 277 
zinc finger protein 295 
zinc finger protein 419 
iroquois homeobox protein 5 
CCR4-NOT transcription complex, 
subunit 7 
heterogeneous nuclear ribonucleoprotein D 
(AU-rich element RNA binding protein l 
37kDa) 
cofactor required for Sp 1 transcriptional 
activation, subunit 9, 33kDa 
KIAA0543 protein 
myeloid/lymphoid or mixed-lineage 
leukemia 5 (trithorax homolog, Drosophila) 
v-rel reticuloendotheliosis viral oncogene 
homolog A, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 3, 
p65 (avian) 
mediator of RNA polymerase II transcription, 
subunit 28 homolog (yeast) 
forkhead box P2 
B-cell receptor-associated protein 31 
huntingtin (Huntington disease) 
BCL2-like 2 
solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 
vanin 3 
52 
0.5394 
5.4609 
3.9637 
2.5750 
5.2743 
1.5869 
3.1788 
1.6756 
2.7444 
2.0479 
3.8393 
1.9891 
1.7897 
5.5106 
15.1966 
5.0099 
4.5855 
2.9707 
0.5823 
0.4342 
p value 
0.0117 
0.0136 
0.0043 
0.0056 
0.0014 
0.0037 
0.0023 
0.0119 
0.0024 
0.0055 
0.0060 
0.0148 
0.0024 
0.0007 
0.0146 
0.0067 
0.0031 
0.0020 
0.0111 
0.0041 
A C02 aconitase 2, mitochondrial 
MAN2Bl mannosidase, alpha, class 2B, member 1 
DDEFLl development and differentiation enhancing 
factor-like 1 
PUM2 pumilio homolog 2 (Drosophila) 
TDG thymine-DNA glycosylase 
ENPP4 ectonucleotide pyrophosphatase/ 
phosphodiesterase 4 (putative function) 
VLDLR very low density lipoprotein receptor 
Lipid metabolism 
PPARA peroxisome proliferative activated receptor, 
alpha 
PLCLl phospholipase C-like 1 
Glycogen metabolism 
PPP1CB protein phosphatase 1, catalytic subunit, 
beta isoform 
Triacylglycerol biosynthesis 
DGAT2 diacylglycerol 0-acyltransferase homolog 2 
(mouse) 
Electron transport 
ACOXL acyl-Coenzyme A oxidase-like 
COX11 COX11 homolog, cytochrome c oxidase 
assembly protein (yeast) 
COX7A2L cytochrome c oxidase subunit VIla 
polypeptide 2 like 
NDUFS7 NADH dehydrogenase (ubiquinone) 
Fe-S protein 7, 20kDa 
(NADH-coenzyme Q reductase) 
NQ02 NAD(P)H dehydrogenase, quinone 2 
Transport 
SCL41Al solute carrier family 41, member 1 
53 
1.9984 0.0025 
3.2674 0.0140 
3.5499 0.0059 
14.4063 0.0116 
2.3615 0.0086 
3.3667 0.0114 
3.5715 0.0056 
0.2626 0.0014 
0.0347 0.0016 
3.6976 0.0033 
0.3131 0.0143 
0.4633 0.0086 
7.1352 0.0040 
8.1928 0.0055 
2.1335 0.0131 
1.7998 0.0048 
0.1772 0.0036 
LTBP2 latent transforming growth factor beta 
binding protein 2 
LRPlB low density lipoprotein-related protein 1 B 
(deleted in tumors) 
RAB4A RAB4A, member RAS oncogene family 
RILP Rab interacting lysosomal protein 
RBP5 retinol binding protein 5, cellular 
MARCO macrophage receptor with collagenous 
structure 
ATP6VOE ATPase, H+ transporting, lysosomal 
9k.Da, VO subunit e 
VPS18 vacuolar protein sorting protein 18 
SPATA13 spermatogenesis associated 13 
SLC9A10 solute carrier family 9, isoform 10 
ATP1A4 ATPase, Na+/K+ transporting, alpha 4 
polypeptide 
DJ971Nl8.2 hypothetical protein DJ971Nl8.2 
C6orf85 chromosome 6 open reading frame 85 
Signal transduction/Signaling pathway 
RSUl Ras suppressor protein 1 
ADCYAPl adenylate cyclase activating 
polypeptide 1 (pituitary) 
TAS2R39 taste receptor, type 2, member 39 
ADCY6 adenylate cyclase 6 
GPR114 G protein-coupled receptor 114 
RHOQ ras homolog gene family, member Q 
GPR23 G protein-coupled receptor 23 
IT GAL integrin, alpha L (antigen CDllA (p180), 
lymphocyte function-associated antigen 1; 
alpha polypeptide) 
ASB1 ankyrin repeat and SOCS box-containing 1 
BCR breakpoint cluster region 
PLEKHMl pleckstrin homology domain containing, 
family M (with RUN domain) member l 
Protein ubiquitination/Ubiquitin cycle 
UBE1 
RNF13 
LNX2 
TRIM33 
UBE2L3 
FBX031 
ubiquitin-activating enzyme E 1 (A1 S9T and 
BN75 temperature sensitivity complementing) 
ring finger protein 13 
ligand of numb-protein X 2 
tripartite motif-containing 33 
ubiquitin-conjugating enzyme E2L 3 
F-box protein 31 
54 
0.0994 
0.5083 
2.2779 
2.3935 
2.7949 
18.9251 
6.2983 
2.3520 
4.3103 
18.8188 
13.4470 
1.8839 
3.3291 
0.0720 
0.5976 
0.5248 
4.6358 
3.8409 
1.7825 
8.9842 
7.2962 
2.4934 
2.1912 
2.8836 
0.5931 
2.5864 
2.3361 
2.0976 
3.7103 
3.3846 
0.0059 
0.0053 
0.0067 
0.0023 
0.0120 
0.0068 
0.0068 
0.0080 
0.0124 
0.0087 
0.0100 
0.0031 
0.0125 
0.0131 
0.0070 
0.0102 
0.0136 
0.0093 
0.0053 
0.0013 
0.0093 
0.0006 
0.0076 
0.0057 
0.0025 
0.0145 
0.0128 
0.0027 
0.0108 
0.0091 
DZIP3 zinc finger DAZ interacting protein 3 
Protein biosynthesis 
MRPL48 
AARSL 
mitochondrial ribosomal protein L48 
alanyl-tRNA synthetase like 
Protein amino acid phosphorylation/dephosphorylation 
NEK7 NIMA (never in mitosis gene a)-related 
kinase 7 
WNK4 WNK lysine deficient protein kinase 4 
PPM2C protein phosphatase 2C, magnesium-
dependent, catalytic subunit 
PTPN3 protein tyrosine phosphatase, non-receptor 
type 3 
PTPRD protein tyrosine phosphatase, receptor 
type, D 
PTPN11 protein tyrosine phosphatase, non-receptor 
type 11 (Noonan syndrome 1) 
DCAMKLl doublecortin and CaM kinase-like 1 
Protein folding 
FIGN fidgetin 
DCPS decapping enzyme, scavenger 
BAG3 BCL2-associated athanogene 3 
SEC63 SEC63-like (S. cerevisiae) 
Cell proliferation 
CDK5RAP3 CDK5 regulatory subunit associated 
protein 3 
EVI5 ecotropic viral integration site 5 
SKP2 S-phase kinase-associated protein 2 (p45) 
Regulation of cell cycle 
LTBP2 latent transforming growth factor beta 
binding protein 2 
CCND2 cyclin D2 
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4.3924 
0.3718 
2.4349 
2.1979 
3.1255 
4.6163 
1.9053 
9.5312 
2.8648 
5.2023 
0.1756 
1.5727 
1.9559 
2.0669 
1.8158 
2.2237 
2.4496 
0.0994 
3.2020 
0.0122 
0.0046 
0.0093 
0.0086 
0.0107 
0.0061 
0.0131 
0.0036 
0.0135 
0.0127 
0.0099 
0.0070 
0.0147 
0.0041 
0.0006 
0.0145 
0.0051 
0.0059 
0.0088 
MCM2 
PHB 
MCM2 minichromosome maintenance 
deficient 2, mitotin (S. cerevisiae) 
prohibitin 
Miscellaneous 
BOLL bol, boule-like (Drosophila) 
EXOSC2 exosome component 2 
MAP2 microtubule-associated protein 2 
SPRR2A small proline-rich protein 2A 
EMD emerin (Emery-Dreifuss muscular dystrophy) 
SECTMl secreted and transmembrane 1 
PHPTl phosphohistidine phosphatase 1 
BACE2 beta-site APP-cleaving enzyme 2 
FLJ11016 hypothetical protein FLJ 11016 
RSAD1 radical S-adenosyl methionine domain 
containing 1 
ARP3BETA actin-related protein 3-beta 
VAPA VAMP (vesicle-associated membrane 
protein)-associated protein A, 33kDa 
HIST1H2AA histone 1, H2aa 
Biological process unknown 
C11orf21 chromosome 11 open reading frame 21 
SLC41Al solute carrier family 41, member 1 
FLJ22639 hypothetical protein FLJ22639 
LOC374946 hypothetical gene supported by AK075558; 
BC021286 
LOC5782l hypothetical protein LOC57821 
MGC15763 hypothetical protein BC008322 
C21orf128 chromosome 21 open reading frame 128 
TSSC4 tumor suppressing subtransferable candidate 4 
C6orf166 chromosome 6 open reading frame 166 
PNPLA5 patatin-like phospholipase domain 
containing 5 
GPHA2 glycoprotein hormone alpha 2 
PHC2 polyhomeotic-like 2 (Drosophila) 
UNC84A unc-84 homolog A (C. elegans) 
RANBP2Ll RAN binding protein 2-like 1 
LENG4 leukocyte receptor cluster (LRC) member 4 
CALU calumenin 
ACTR1B ARP1 actin-related protein 1 homolog B, 
centractin beta (yeast) 
OLFM4 olfactomedin 4 
TDRKH tudor and KH domain containing 
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2.1924 0.0101 
1.7153 0.0040 
0.1625 0.0060 
0.3446 0.0012 
0.0626 0.0058 
0.6369 0.0100 
2.8855 0.0022 
1.9046 0.0108 
4.1273 0.0008 
3.8050 0.0062 
4.0256 0.0052 
1.9727 0.0009 
1.8156 0.0025 
2.5508 0.0118 
1.6043 0.0039 
0.2923 0.0028 
0.1772 0.0036 
0.2401 0.0055 
0.6390 0.0070 
0.3656 0.0072 
0.2782 0.0090 
0.3822 0.0111 
0.2760 0.0125 
0.6383 0.0127 
0.4493 0.0056 
0.5797 0.0066 
0.350 l 0.0039 
0.1983 0.0079 
3.9948 0.0059 
2.8539 0.0149 
2.2629 0.0131 
6.6772 0.0103 
9.9232 0.0113 
129.9912 0.0073 
DDX52 DEAD (Asp-Glu-Ala-Asp) box 2.4363 0.0066 
polypeptide 52 
TTC18 tetratricopeptide repeat domain 18 34.2659 0.0096 
PPRC1 peroxisome proliferative activated receptor, 2.2269 0.0128 
gamma, coactivator-related 1 
KIAA0853 KIAA0853 2.3708 0.0131 
HS6ST3 heparan sulfate 6-0-sulfotransferase 3 2.8146 0.0050 
GALNTL4 UDP-N-acetyl-alpha-D-galactosamine: 7.4970 0.0090 
polypeptide N -acetylgalactosaminyltransferase-
like 4 
TTC15 tetratricopeptide repeat domain 15 3.6655 0.0023 
NUDT12 nudix (nucleoside diphosphate linked moiety 5.5836 0.0089 
X)-type motif 12 
C9orfl40 chromosome 9 open reading frame 140 3.2908 0.0115 
SUV420H1 suppressor of variegation 4-20 homolog 1 5.3170 0.0118 
(Drosophila) 
PCNXL2 pecanex-like 2 (Drosophila) 2.6497 0.0109 
SLITRK6 SLIT and NTRK-like family, member 6 3.8098 0.0083 
FTO fatso 2.1995 0.0001 
KIAA1155 KIAA1155 protein 2.8633 0.0003 
FLJ39441 hypothetical protein FLJ39441 65.3742 0.0011 
HBA2 hemoglobin, alpha 2 1.8548 0.0015 
MGC14839 similar to RIKEN eDNA 231 0030G06 gene 3.1291 0.0016 
TDH L-threonine dehydrogenase 5.4626 0.0020 
MGC3234 hypothetical protein MGC3234 2.2071 0.0022 
KIAA0754 KIAA0754 protein 2.6722 0.0023 
FLJ90024 fasting-inducible integral membrane protein 3.0180 0.0024 
TM6P1 
[DKFZ putative lysophosphatidic acid acyltransferase 4.3404 0.0080 
p586M1819] 
ARMCX6 armadillo repeat containing, X-linked 6 3.4875 0.0025 
RP11-19J3.3 similar to hypothetical protein 2.5574 0.0031 
IFI44L interferon-induced protein 44-like 1.7523 0.0032 
ZNF419 zinc finger protein 41 9 1.5869 0.0037 
IL8RBP interleukin 8 receptor, beta pseudogene 2.2217 0.0041 
TTLL2 tubulin tyrosine ligase-like family, member 2 18.6815 0.0050 
FLJ21019 hypothetical protein FLJ21 0 19 1.7953 0.0050 
DCL-1 type I transmembrane C-type lectin receptor 5.0830 0.0050 
DCL-1 
PSIP1 PC4 and SFRS 1 interacting protein 1 2.4778 0.0052 
KIAA1957 KIAA1957 3.5739 0.0052 
LOC340281 hypothetical protein LOC340281 3.5030 0.0053 
[DKFZP547 DKFZP547El010 protein 2.2962 0.0054 
E1010] 
MGC27165 hypothetical protein M GC27165 2.5221 0.0059 
LOC284889 hypothetical protein LOC284889 2.4647 0.0061 
[DKFZp762 hypothetical protein DKFZp762K222 4.7026 0.0066 
K222] 
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[DKFZp761 hypothetical protein DKFZp761El98 47.9190 0.0067 
E198] 
LOC63920 transposon-derived Buster3 transposase-like 11.5783 0.0068 
C9orfl05 chromosome 9 open reading frame 105 12.6042 0.0071 
T1A-2 lung type-I cell membrane-associated 1.9100 0.0073 
glycoprotein 
C10orf24 chromosome 10 open reading frame 24 1.8704 0.0074 
TCFL4 transcription factor-like 4 4.4176 0.0074 
LOC401967 similar to KIAA1693 protein 3.6775 0.0078 
VPS18 vacuolar protein sorting protein 18 2.3520 0.0080 
[DKFZp586 putative lysophosphatidic acid acyltransferase 4.3404 0.0080 
M1819] 
PLEKHA6 pleckstrin homology domain containing, 5.2061 0.0082 
family A member 6 
ZD52F10 dermokine 3.9068 0.0093 
PNMA5 paraneoplastic antigen like 5 2.4504 0.0100 
MOBK1B MOB!, Mps One Binder kinase activator-like 2.9382 0.0101 
1B (yeast) 
C6orfl0 chromosome 6 open reading frame 1 0 3.4673 0.0102 
LOC92482 hypothetical protein LOC92482 1.9243 0.0105 
LOC126755 hypothetical protein LOC126755 9.2021 0.0116 
[DKFZp762 hypothetical protein DKFZp762C1112 2.4060 0.0116 
C1112] 
CBWD2 COBW domain containing 2 4.7765 0.0118 
TA-PP2C T -cell activation protein phosphatase 2C 3.6550 0.0126 
MGC34805 hypothetical protein MGC34805 2.1248 0.0128 
LOC285749 hypothetical protein LOC285749 5.2981 0.0130 
MGC32124 hypothetical protein MGC32124 6.0151 0.0132 
NCDN neurochondrin 3.3893 0.0138 
FLJ40201 hypothetical protein FLJ4020 1 2.9315 0.0139 
LOC163782 hypothetical protein LOC 163 782 11.4807 0.0142 
MGC12760 hypothetical protein MGC12760 2.4207 0.0144 
FAM26C family with sequence similarity 26, 2.4931 0.0146 
member C 
FLJ43860 FLJ43860 protein 6.9144 0.0146 
LOC285908 hypothetical protein LOC285908 2.6054 0.0144 
FNDC3A fibronectin type III domain containing 3A 3.2624 0.0149 
*Fold change indicates pre-exercise intensity values divided by post-exercise values. 
Classification based on GOTM software (http://genereg.ornl.gov.gotm). Only genes with 
identified HUGO names are included. 
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Table 3.15 Significantly down- and up-regulated genes, classified by biological process, 
of obese subjects in response to short-term exercise. 
HUGO name Description 
Regulation of transcription 
RBPSUH recombining binding protein suppressor 
of hairless (Drosophila) 
ZFPM2 zinc finger protein, multitype 2 
SSX5 synovial sarcoma, X breakpoint 5 
HOXB9 homeo box B9 
SOX3 SRY (sex determining region Y)-box 3 
ZBTB12 zinc finger and BTB domain containing 12 
ZNF85 zinc finger protein 85 (HPF4, HTF 1) 
ZNF146 zinc finger protein 146 
ZNF586 zinc finger protein 586 
ASCC3 activating signal cointegrator 1 complex 
subunit 3 
HES2 hairy and enhancer of split 2 (Drosophila) 
Proteolysis and peptidolysis 
PCSKl 
MSTP9 
CPBl 
F9 
UBD 
MMP19 
RNPEP 
ADAM33 
Apoptosis 
PLAGLl 
PHLDA2 
proprotein convertase subtilisin/kexin type 1 
macrophage stimulating, pseudogene 9 
carboxypeptidase B 1 (tissue) 
coagulation factor IX (plasma 
thromboplastic component, Christmas 
disease, hemophilia B) 
ubiquitin D 
matrix metalloproteinase 19 
arginy1 aminopeptidase (aminopeptidase B) 
a disintegrin and metalloproteinase 
domain 33 
pleiomorphic adenoma gene-like l 
pleckstrin homology-like domain, 
family A, member 2 
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Fold change* 
0.2260 
0.4756 
0.3969 
4.2387 
3.4097 
11.7818 
5.2315 
548.5253 
9.4432 
7.9331 
9.1263 
0.4478 
0.0618 
0.1005 
0.3673 
2.6744 
2.5244 
16.0016 
10.0491 
0.61 ()] 
2.5743 
p value 
0.0040 
0.0011 
0.0042 
0.0007 
0.0108 
0.0019 
0.0067 
0.0071 
0.0062 
0.0084 
0.0054 
0.0046 
0.0094 
0.0038 
0.0065 
0.0120 
0.0141 
0.0018 
0.0078 
0.0022 
0.0117 
Immune response 
IGHM 
CST7 
CD96 
LILRA2 
LTB 
BPI 
immunoglobulin heavy constant mu 
cystatin F (leukocystatin) 
CD96 antigen 
leukocyte immunoglobulin-like receptor, 
subfamily A (with TM domain), member 2 
lymphotoxin beta (TNF superfamily, 
member 3) 
bactericidal/permeability-increasing 
protein 
Inflammatory response 
IL1R1 interleukin 1 receptor, type I 
ITCH itchy homolog E3 ubiquitin protein 
ligase (mouse) 
S100Al2 S 1 00 calcium binding protein A 12 
( calgranulin C) 
Metabolism 
ST3GAL5 ST3 beta-galactoside alpha-2,3-
sialyltransferase 5 
CERK ceramide kinase 
ITIH5 inter-alpha (globulin) inhibitor H5 
AKR7A3 aldo-keto reductase family 7, member A3 
(aflatoxin aldehyde reductase) 
GK glycerol kinase 
SMPD3 sphingomyelin phosphodiesterase 3, neutral 
membrane (neutral sphingomyelinase II) 
CA5BL carbonic anhydrase VB-like 
AGPAT5 1-acylglycerol-3-phosphate 0-acyltransferase 
5 (lysophosphatidic acid acyltransferase, 
epsilon) 
ASAH2 N-acylsphingosine amidohydrolase 
(non-lysosomal ceramidase) 2 
Lipid metabolism 
SLC27A6 solute carrier family 27 
(fatty acid transporter), member 6 
ALDH3A2 aldehyde dehydrogenase 3 family, 
member A2 
60 
0.6742 
0.1476 
2.6522 
11.4194 
1.5402 
9.3217 
0.5342 
0.5677 
4.0037 
0.5338 
0.5205 
0.3362 
1.9419 
4.6494 
11.7743 
4.7331 
2.3159 
2.3289 
0.5183 
3.2094 
0.0077 
0.0061 
0.0127 
0.0129 
0.0123 
0.0129 
0.0085 
0.0082 
0.0140 
0.0071 
0.0003 
0.0120 
0.0046 
0.0083 
0.0118 
0.0036 
0.0088 
0.0006 
0.0119 
0.0099 
Phospholipid biosynthesis 
GPAM glycerol-3-phosphate acyltransferase, 0.4116 0.0036 
mitochondrial 
Transport 
KCNH7 potassium voltage-gated channel, 0.4359 0.0145 
subfamily H ( eag-related), member 7 
ATCAY ataxia, cerebellar, Cayman type ( caytaxin) 0.2881 0.0004 
SLC8A1 solute carrier family 8 (sodium/calcium 0.6177 0.0105 
exchanger), member 1 
ARF3 ADP-ribosylation factor 3 0.4129 0.0112 
SLC4A5 solute carrier family 4, sodium 0.5821 0.0009 
bicarbonate cotransporter, member 5, 
SLC39A4 solute carrier family 39 (zinc transporter), 6.6898 0.0110 
member 4 
SCAMP2 secretory carrier membrane protein 2 6.3755 0.0095 
COPG2 coatomer protein complex, subunit 2.2355 0.0081 
gamma2 
HFE hemochromatosis 23.1734 0.0136 
ITPR3 inositol 1 ,4,5-triphosphate receptor, 2.2531 0.0126 
type 3 
KCNJ13 potassium inwardly-rectifying channel, 43.6760 0.0052 
subfamily J,member 13 
KCNK2 potassium channel, subfamily K, 5.8440 0.0122 
member 2 
SLC16A3 solute carrier family 16 (monocarboxylic 1.9997 0.0064 
acid transporters), member 3 
SYTL4 synaptotagmin-like 4 (granuphilin-a) 13.4468 0.0028 
ARL5 ADP-ribosylation factor-like 5 2.2058 0.0017 
NRAP nebulin-related anchoring protein 2.8601 0.0027 
Lipid transport 
APOL6 apolipoprotein L, 6 0.1809 0.0005 
Signal transduction/Signaling pathway 
GNB4 guanine nucleotide binding protein 0.6248 0.0070 
(G protein), beta polypeptide 4 
AGTR1 angiotensin II receptor, type 1 0.2100 0.0005 
CHRNA5 cholinergic receptor, nicotinic, alpha 0.5776 0.0024 
polypeptide 5 
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OR6A2 olfactory receptor, family 6, subfamily A, 
member 2 
EPOR erythropoietin receptor 
PIK4CA phosphatidylinositol 4-kinase, catalytic, 
alpha polypeptide 
DEPDCl DEP domain containing 1 
GPR132 G protein-coupled receptor 132 
HTR4 5-hydroxytryptamine (serotonin) receptor 4 
RAB27A RAB27 A, member RAS oncogene family 
DNA repair/Base-excision repair/DNA damage response 
DMCl DMC1 dosage suppressor ofmckl homolog, 
meiosis-specific homologous recombination 
(yeast) 
FANCF Fanconi anemia, complementation group F 
APEXl APEX nuclease (multifunctional DNA 
repair enzyme) 1 
GTSE1 G-2 and S-phase expressed 1 
Defense response 
NCF4 neutrophil cytosolic factor 4, 40kDaP 
DNA methylation 
DISCI disrupted in schizophrenia 1 
DNMT3B DNA ( cytosine-5-)-methyltransferase 3 
beta 
Chromatin Modification 
EP400 
SMARCCl 
Development 
LM02 
NUMB 
PLXNA2 
ElA binding protein p400 
SWIISNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, 
member 1 
LIM domain only 2 (rhombotin-like 1) 
numb homolog (Drosophila) 
plexin A2 
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0.3355 
2.9297 
1.9830 
2.1030 
22.6237 
2.1086 
48.9776 
0.3759 
1.9348 
4.9311 
6.2095 
2.6028 
0.3868 
7.3024 
2.1558 
4.8370 
1.9804 
2.5043 
3.7048 
0.0140 
0.0032 
0.0080 
0.0124 
0.0098 
0.0010 
0.0044 
0.0051 
0.0010 
0.0010 
0.0045 
0.0101 
0.0016 
0.0010 
0.0099 
0.0122 
0.0085 
0.0085 
0.0113 
Protein ubiquitination/Ubiquitin cycle 
C20orf18 
C17orf27 
RNF5 
CUL3 
FBX044 
Protein repair 
SEPXl 
chromosome 20 open reading frame 18 
chromosome 17 open reading frame 27 
ring finger protein 5 
cullin 3 
F -box protein 44 
selenoprotein X, 1 
Protein biosynthesis 
FNBPl formin binding protein 1 
Protein amino acid phosphorylation 
EPHA8 EPH receptor A8 
PRKACA protein kinase, cAMP-dependent, catalytic, 
alpha 
Complement activation 
C4BPA complement component 4 binding 
protein, alpha 
Cell cycle 
ASPM asp (abnormal spindle)-like, microcephaly 
associated (Drosophila) 
BINI bridging integrator 1 
BRDT bromodomain, testis-specific 
TCF19 transcription factor 19 (SC 1) 
MADILl MADl mitotic arrest deficient-like 1 (yeast) 
KNTCl kinetochore associated 1 
Cell adhesion 
ARHGAP5 Rho GTPase activating protein 5 
CYR61 cysteine-rich, angiogenic inducer, 61 
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1.5315 
4.2055 
3.0652 
6.4005 
1.5814 
0.6052 
1.9508 
0.4522 
6.2556 
2.5218 
12.5706 
2.5330 
2.6835 
3.0190 
2.4644 
3.1984 
3.2735 
5.0410 
0.0101 
0.0051 
0.0046 
0.0063 
0.0021 
0.0086 
0.0062 
0.0109 
0.0075 
0.0136 
0.0106 
0.0047 
0.0135 
0.0001 
0.0104 
0.0005 
0.0029 
0.0114 
Miscellaneous 
LSM6 LSM6 homolog, U6 small nuclear RNA 0.6058 0.0034 
associated (S. cerevisiae) 
phosphatase 1 
TXNDC2 thioredoxin domain containing 2 0.3333 0.0063 
(spermatozoa) 
SlOOAll S 1 00 calcium binding protein All 0.5571 0.0107 
( calgizzarin) 
FKBPlB FK506 binding protein 1B, 12.6 kDa 3.0337 0.0103 
CPS1 carbamoyl-phosphate synthetase 1, 2.2007 0.0133 
mitochondrial 
IFRD1 interferon-related developmental 3.6688 0.0140 
regulator 1 
MMD2 monocyte to macrophage differentiation- 2.9010 0.0132 
associated 2 
MYH10 myosin, heavy polypeptide 10, non-muscle 3.7555 0.0135 
FRAS1 Fraser syndrome 1 8.9096 0.0067 
HIST1H2BN histone 1, H2bn 10.7272 0.0072 
HIST1H3H histone 1, H3 h 2.9266 0.0103 
HARS2 histidyl-tRNA synthetase 2 799.5183 0.0120 
Biological process unknown 
FLJ10647 hypothetical protein FLJ 1064 7 0.5556 4.34E-05 
CST3 cystatin C (amyloid angiopathy and cerebral 0.3867 0.0005 
hemorrhage) 
LOC51145 erythrocyte transmembrane protein 0.4922 0.0008 
KIR2DS4 killer cell immunoglobulin-like receptor, 0.5542 0.0009 
two domains, short cytoplasmic tail, 4 
FLJ11017 hypothetical protein FLJ11017 0.4463 0.0011 
FLJ20712 hypothetical protein FLJ20712 0.3826 0.0016 
FLJ30313 hypothetical protein FLJ30313 0.6121 0.0018 
DDI2 DNA-damage inducible protein 2 0.1900 0.0020 
MGC41945 hypothetical protein M GC41945 0.4552 0.0050 
FLJ90680 FLJ90680 protein 0.3901 0.0056 
C9orf9 chromosome 9 open reading frame 9 0.5910 0.0061 
ADHFE1 alcohol dehydrogenase, iron containing, 1 0.5841 0.0070 
FLJ22795 hypothetical protein FLJ22795 0.6537 0.0071 
LOC339290 hypothetical protein LOC339290 0.5866 0.0074 
ZNF552 zinc finger protein 552 0.4226 0.0075 
KIAA1539 KIAA1539 0.4662 o.omn 
RUFY2 RUN and FYVE domain containing 2 0.4475 0.0090 
KIAA0420 KIAA0420 gene product 0.0938 0.0101 
KIAA1666 KIAA1666 protein 0.5293 0.0108 
LOC55565 hypothetical protein LOC55565 0.5013 0.0123 
SYNJ2 synaptojanin 2 0.5414 0.0123 
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LOC57146 promethin 0.4374 0.0123 
PKHD1 polycystic kidney and hepatic disease 1 0.3666 0.0131 
R29124 1 carcinoembryonic antigen-related cell 0.2862 0.0149 
adhesion molecule 
(autosomal recessive) 
CTDSPl CTD (carboxy-terminal domain, RNA 0.3988 0.0112 
polymerase II, polypeptide A) small 
FANCD2 Fanconi anemia, complementation group D2 3.1373 0.0110 
SURF4 surfeit 4 1.9436 0.0089 
C5orfl8 chromosome 5 open reading frame 18 4.2410 0.0016 
TRIM16 tripartite motif-containing 16 2.3662 0.0040 
CKMT1 creatine kinase, mitochondrial 1 (ubiquitous) 2.1000 0.0059 
C20orf179 chromosome 20 open reading frame 1 79 2.5898 0.0020 
DPPA2 developmental pluripotency associated 2 50.2380 0.0125 
TTC21A tetratricopeptide repeat domain 21 A 5.9986 0.0106 
ZCWCCl zinc finger, CW type with coiled-coil domain 1 3.2077 0.0003 
CLDN15 claudin 15 8.4307 0.0147 
C20orf22 chromosome 20 open reading frame 22 10.3375 0.0120 
DHX35 DEAH (Asp-Glu-Ala-His) box polypeptide 35 2.3807 0.0140 
C10orf81 chromosome 1 0 open reading frame 81 2.5719 0.0057 
ZNF237 zinc finger protein 23 7 15.9584 0.0059 
PSCDBP pleckstrin homology, Sec7 and coiled-coil 2.3044 0.0078 
domains, binding protein 
ASTN2 astrotactin 2 1.8333 0.0101 
HIST2H3C histone 2, H3c 3.5299 0.0003 
DERP6 S-phase 2 protein 2.1299 0.0008 
LNK lymphocyte adaptor protein 2.6924 0.0012 
LOC92305 hypothetical protein BC009331 6.0684 0.0015 
MGC16028 MGC16028 similar to RIKEN eDNA 4.4320 0.0017 
1700019E19 gene 
SECP43 tRNA selenocysteine associated protein 24.8545 0.0017 
ANKRD29 ankyrin repeat domain 29 56.6436 0.0019 
KIAA0746 KIAA07 46 protein 3.1993 0.0022 
[DKFZp566 putative MAPK activating protein PM20, 6.9359 0.0022 
C0424] PM21 
[DKFZp762 hypothetical protein DKFZp762Il37 2.6880 0.0024 
I137] 
FLJ43654 FLJ43654 protein 1.7922 0.0025 
KIAA1799 KIAA1799 protein 1.7388 0.0030 
HHIP hedgehog interacting protein 4092.3492 0.0038 
PSD3 pleckstrin and Sec7 domain containing 3 2.5929 0.0039 
NRG4 neuregulin 4 3.2214 0.0043 
FLJ20323 hypothetical proLcin FLJ20323 4.0887 0.0047 
FAM33A family with sequence similarity 33, 2.9785 0.0053 
member A 
PTGES2 prostaglandin E synthase 2 2.6718 0.0054 
RAMP RA-regulated nuclear matrix-associated 2.9757 0.0055 
protein 
KIAA0913 KIAA0913 5.6352 0.0056 
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FLJ12529 pre-mRNA cleavage factor I, 59 k.Da subunit 3.0348 0.0057 
KIAA1755 KIAA1755 protein 4.2521 0.0061 
[DKFZP586 regeneration associated muscle protease 5.7173 0.0064 
H2123] 
HSU79274 protein predicted by clone 23733 3.4482 0.0072 
HIT-40 zinc finger protein HIT -40 6.7390 0.0073 
LOC284021 hypothetical protein LOC284021 3.1845 0.0075 
OBSCN obscurin, cytoskeletal calmodulin and titin- 5.5655 0.0076 
interacting RhoGEF 
MGC45491 hypothetical protein MGC45491 8.3547 0.0077 
CSS3 chondroitin sulfate synthase 3 5.1775 0.0078 
XIST X (inactive )-specific transcript 18.2111 0.0083 
ODC-p ornithine decarboxylase-like 3.0672 0.0095 
LOC349408 hypothetical protein LOC349408 2.4370 0.0097 
PSD pleckstrin and Sec7 domain containing 7.2301 0.0101 
FLJ42953 FLJ42953 protein 2.9393 0.0103 
KIAA0753 KIAA0753 gene product 2.4950 0.0103 
MGC27277 hypothetical protein MGC27277 4.4653 0.0104 
FLJ31164 hypothetical protein FLJ31164 2.4956 0.0108 
MAC30 hypothetical protein MAC30 20.4965 0.0109 
FLJ21736 esterase 31 2.9579 0.0112 
LOC284454 hypothetical protein LOC284454 168.3068 0.0118 
MGC34821 hypothetical protein MGC34821 2.5772 0.0119 
CDCA2 cell division cycle associated 2 9.7505 0.0125 
GPR55 G protein-coupled receptor 55 5.7368 0.0126 
Ells! hypothetical protein Ells 1 3.2652 0.0129 
AF1Q ALLl-fused gene from chromosome 1 q 3.1241 0.0134 
CSGlcA-T chondroitin sulfate glucuronyltransferase 3.2605 0.0134 
*Fold change indicates pre-exercise intensity values divided by post-exercise values. 
Classification based on GOTM software (http://genercg.oml.gov.gotm). Only genes with 
identified HUGO names are included. 
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possible FDR. Many genes are functionally closely associated with each other, and thus 
they are not theoretically independent. Consequently, the differentially expressed genes 
can be categorized into a number of functional groups. Thus, taking this factor into 
consideration, the FDR would be less that 5% for both lean and obese samples. 
In the subcutaneous adipose tissue oflean samples, in response to 7 days of 
aerobic exercise, there was a significant (p < 0.01) enrichment of down-regulated genes in 
13 gene ontology categories (Figure 3.1), such as dephosphorylation, macromolecule 
metabolism, negative regulation of metabolism, magnesium ion binding, phosphoprotein 
phosphatase activity, and primary active transporter activity to name a few. There was no 
significant enrichment of up-regulated genes in gene ontology categories for the lean 
samples. In the subcutaneous adipose tissue of obese samples, in response to 7 days of 
aerobic exercise at the same intensity level, there was a significant enrichment of down-
regulated genes in 5 gene ontology categories (Figure 3.2), according to gene ontology 
analysis, such as membrane lipid metabolism, mitotic and cell cycle checkpoint, and 
transition metal, especially zinc, ion binding in obese samples. As well, there was a 
significant enrichment of up-regulated genes in l 0 gene ontology categories for obese 
samples (Figure 3.3), such as membrane lipid metabolism, sphingolipid metabolism, 
ceramide metabolism, serine-type endopeptidase activity, and protease and endopeptidase 
inhibitor activity to name a few. 
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Figure 3.1 Enrichment of down-regulated genes in 13 gene ontology categories (in 
biological process and molecular function) oflean subjects in response to short-term 
aerobic exercise (p < 0.01 ). Genes may appear in more than one ontology category. 
Significance assessed using the Gene Ontology Tree Machine 
(http://genereg.oml.gov/~gotm). 
68 
20 
18 
16 
14 
UJ 
Q) 
-Observed 
-Expected 
c 12 Q) 
0) 
...... 
0 10 ,_ 
Q) 
.0 
E 8 
::J 
z 
6 
4 
2 
0 
-~ .., ... 
*~ q,'-' 
~ 
-~ ~ $ 
Figure 3.2 Enrichment of down-regulated genes in 5 gene ontology categories (in 
biological process and molecular function) of obese subjects in response to short-tenn 
aerobic exercise (p < 0.01). Genes may appear in more than one ontology category. 
Significance assessed using the Gene Ontology Tree Machine 
(http://genereg.oml.gov/~gotm). 
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Figure 3.3 Enrichment of up-regulated genes in 10 gene ontology categories (in 
biological process and molecular function) of obese subjects in response to short-term 
aerobic exercise (p < 0.01). Genes may appear in more than one ontology category. 
Significance assessed using the Gene Ontology Tree Machine 
(http://genereg.oml.gov/~gotm). 
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In the abdominal subcutaneous adipose tissue lean subjects, in response to aerobic 
exercise, 53 potential genes, without defined HUGO names, were differentially expressed 
(14 up regulated and 39 down regulated) (Table 3.16). Eighty potential genes, without 
defined HUGO names, were differentially expressed (31 up regulated and 49 down 
regulated) in obese subjects (Table 3.17). 
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Table 3.16 Significantly down- and up-regulated genes, without HUGO names, in lean 
subjects in response to short-term exercise 
Systematic name Description Fold change p value 
Down-regulated 
AK057476 Homo sapiens eDNA FLJ32914 2.5268 0.0001 
fis, clone TESTI2006409 
A 23 P209527 Unknown 3.4973 0.0016 
A 24 P58607 Unknown 2.0678 0.0018 
THC220710l ALU6_HUMAN (P39193) Alu 2.0360 0.0024 
subfamily SP sequence contamination 
warning entry, partial (18%) 
ENST00000355343 Seven transmembrane helix receptor 3.1860 0.0025 
[Source: U niprot/SPTREMBL; 
Acc:Q8NH82] 
AF289590 Homo sapiens clone pp7583 11.5804 0.0027 
unknown mRNA 
NP109438 copper transporting P-type ATPase, 5.4189 0.0033 
ATP7B [human, Wilson disease 
patient, Peptide Partial, 38 aa] 
AL522024 Homo sapiens NEUROBLASTOMA 10.1536 0.0036 
COT l 0-NORMALIZED Homo sapiens 
eDNA clone CSODB007YI07 3-PRIME, 
mRNA sequence 
ENST00000314984 Seven transmembrane helix receptor 3.7717 0.0047 
[Source: Uniprot/SPTREMBL; 
Acc:Q8NH35] 
AK096567 Homo sapiens eDNA FLJ39248 fis, 18.5505 0.0051 
clone OCBBF2008586 
AK000038 Homo sapiens eDNA FLJ20031 fis, 4.0084 0.0051 
clone ADSU02180 
AV739766 CB Homo sapiens eDNA clone 4.8664 0.0054 
CBDAGB02 5', mRNA sequence 
THC2169084 Q99P30 Coenzyme A diphosphatase, 2.7922 0.0056 
partial (64%) 
AK023328 Homo sapiens eDNA FLJ13266 fis, 3.8714 0.0060 
clone OV ARC 1000960 
AL834124 Homo sapiens mRNA; eDNA 2.0906 0.0068 
DKFZp547Cl62 (from clone 
DKFZp547C162) 
A 24 P298099 Unknown 2.8402 0.0077 
A 32 P8806 Unknown 1.6836 0.0079 
A 24 P84112 Unknown 2.0843 0.0079 
THC2184722 Unknown 7.7821 0.0082 
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BM678922 UI-E-EOO-ahx-b-23-0-UI.sl UI-E- 3.1434 0.0086 
EOO Homo sapiens eDNA clone UI-
E-EOO-ahx-b-23-0-UI 3', mRNA 
sequence 
BC015836 Homo sapiens, clone IMAGE: 2.2674 0.0087 
4293240, mRNA 
AY358732 Homo sapiens clone DNA135173 6.7423 0.0089 
KVVM3106 (UNQ3106) mRNA, 
complete cds 
THC2141315 Unknown 3.3237 0.0094 
THC2038739 Unknown 6.0296 0.0102 
THC2198832 Q6IFN5 Olfactory receptor 2.0429 0.0102 
OR19-14, partial (71%) 
A 23 P128897 Unknown 3.8107 0.0110 
A 32 P78285 Unknown 3.3296 0.0110 
A 24 P325533 Unknown 12.3972 0.0117 
BI062366 IL3-UT0117-160301-502-D08 12.4723 0.0119 
UTO 117 Homo sapiens eDNA, 
mRNA sequence 
THC2096232 Q7Z6F8 M GC 18079, partial (7%) 5.1552 0.0125 
A 32 P215745 Unknown 2.6438 0.0133 
A 24 P349539 Unknown 1.7014 0.0133 
AF279782 Homo sapiens clone P1 NTera2D1 3.0588 0.0135 
teratocarcinoma mRNA 
AI190733 qd61 aO l.x 1 Soares_ testis_ NHT 2.3098 0.0138 
Homo sapiens eDNA clone IMAGE: 
1733928 3', mRNA sequence 
BG612665 602641001F1 NIH MGC 61 5.3988 0.0142 
- -
Homo sapiens eDNA clone IMAGE: 
4771873 5', mRNA sequence 
A 24 P307075 Unknown 2.2367 0.0142 
A 32 P228601 Unknown 1.8444 0.0143 
A 23 P13232 Unknown 4.0263 0.0147 
A 24 P281683 Unknown 2.1222 0.0149 
Up-regulated 
AK023038 Homo sapiens eDNA FLJ12976 t!s, 0.6633 0.0005 
clone NT2RP2006258 
THC2101189 Unknown 0.2889 0.0007 
BM725480 UI-E-EJO-aic-p-22-0-UI.rl UI-E-EJO 0.2803 0.0012 
Homo sapiens eDNA clone UI-E-EJO-
aie-p-22-0-UI 5', mRNA sequence 
CD630738 CD630738 56066364H1 FLP Homo 0.4062 0.0014 
sapiens eDNA, mRNA sequence 
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THC2164534 ALUl HUMAN (P39188) Alu 0.3526 0.0017 
subfamily J sequence contamination 
warning entry, partial (12%) 
AK023773 Homo sapiens eDNA FLJ13711 fis, 0.5698 0.0029 
clone PLACE2000379 
THC2181597 Unknown 0.3074 0.0042 
U44029 Human cathepsin B mRNA, 5' UTR 0.2075 0.0047 
variant 
AK024241 Homo sapiens eDNA FLJ14179 tis, 0.3980 0.0059 
clone NT2RP2003668 
A 32 Pl8300 Unknown 0.3677 0.0071 
THC2089776 Unknown 0.2350 0.0078 
THC2055711 Unknown 0.3948 0.0103 
THC2141633 Q7NI46 (Q7NI46) Cytochrome c550, 0.2834 0.0134 
partial (8%) 
A 23 P317548 Unknown 0.4220 0.0149 
*Fold change indicates pre-exercise intensity values divided by post-exercise values. 
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Table 3.17 Significantly down- and up-regulated genes, without HUGO names, in obese 
subjects in response to short-term exercise 
Systematic name Description Fold change p value 
Down-regulated 
K03192 Human cytochrome P-450 mRNA, 1.8421 0.0004 
partial 
A 24 P929413 Unknown 4.7903 0.0006 
A 32 P31206 Unknown 9.0128 0.0007 
THC2203406 Unknown 3.7121 0.0009 
A 24 Pl95454 Unknown 7.6128 0.0011 
A 24 P101181 Unknown 4.5782 0.0014 
THC2123705 Unknown 1.8557 0.0015 
AW964144 EST376217 MAGE resequences, 3.3960 0.0017 
MAGH Homo sapiens eDNA, mRNA 
Sequence 
THC2210842 Unknown 15.0467 0.0019 
ENST00000321887 Unknown 2.5422 0.0024 
AK022793 Homo sapiens eDNA FLJ12731 fis, 5.2731 0.0025 
clone NT2RP2000 108 
CD388102 AGENCOURT 14302060 Nill 80.4062 0.0026 
- -
MGC _173 Homo sapiens eDNA 5', 
mRNA sequence 
A 32 P105893 Unknown 2.7567 0.0029 
THC2199235 GPS2 HUMAN (Q13227) G protein 2.9029 0.0029 
pathway suppressor 2 (GPS2 protein), 
partial (52%) 
ENST000003083 84 MHC class II HLA-SX-alpha gene. 2.9316 0.0029 
(Fragment). [Source: Uniprot/ 
SPTREMBL;Acc:Q30 181] 
BM665043 UI-E-CQ 1-aev-p-07 -0-UI.s 1 UI-E- 4.1893 0.0033 
CQ1 Homo sapiens eDNA clone UI-E-
CQl-aev-p-07-0-UI 3', mRNA sequence 
A 23 P134704 Unknown 2.5086 0.0037 
BU618438 BU618438 UI-H-FH1-bfg-c-03-0-UI. 7.7169 0.0038 
s1 NCI_CGAP _FH1 Homo sapiens 
eDNA clone UI-H-FH1-bfg-c-03-0-
UI 3', mRNA sequence 
CR611166 full-length eDNA clone 3.5653 0.0040 
CSOCAP007YF02 ofThymus ofHomo 
sapiens (human) 
BI261159 BI261159 602968272F1 NIH_MGC 5.7604 0.0047 
-
12 Homo sapiens eDNA clone IMAGE: 
5107840 5', mRNA sequence 
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AL359605 Homo sapiens mRNA; eDNA 33.4759 0.0048 
DKFZp547G036 (from clone 
DKFZp547G036) 
A 24 P383751 Unknown 20.3587 0.0054 
BQ632351 BQ632351 il25h07.x1 HR85 islet 3.2538 0.0057 
Homo sapiens eDNA clone IMAGE: 
6031332 3' similartoTR:Q9Z2Xl 
Q9Z2X1 RIBONUCLEOPROTEIN 
F. ;, mRNA sequence 
AW178774 A W17877 4 PMO-HTO 123-310899- 3.3274 0.0059 
00 1-b08 HTO 123 Homo sapiens 
eDNA, mRNA sequence 
ENST00000344214 Unknown 3.9833 0.0060 
BC002886 Homo sapiens eDNA clone MGC: 4.0206 0.0063 
11241 IMAGE:3939857, complete cds 
AF075119 Homo sapiens full length insert eDNA 35.4745 0.0069 
ZD26E01 
THC2054435 ALU1_HUMAN (P39188) Alu 3.2213 0.0079 
subfamily J sequence contamination 
warning entry, partial (13%) 
A 23 P28927 Unknown 4.1034 0.0090 
THC2177003 Unknown 2.4535 0.0090 
A 24 P307126 Unknown 9.1521 0.0093 
BC011136 Homo sapiens, clone IMAGE: 2.8523 0.0098 
3448872, mRNA, partial cds 
THC2166062 Unknown 12.7600 0.0099 
THC2210983 ALUl_HUMAN (P39188) Alu 1.8061 0.0102 
subfamily J sequence contamination 
warning entry, partial (7%) 
A 24 P268474 Unknown 4.6119 0.0103 
A 24 P268474 Unknown 4.6119 0.0 l 03 
AK022865 Homo sapiens eDNA FLJ12803 tis, 1.9371 0.0105 
clone NT2RP20021 72 
AK124847 Homo sapiens eDNA FLJ42857 fis, 10.7109 0.0105 
clone BRHIP2009340 
THC2164534 ALU1_HUMAN (P39188) Alu 2.0865 0.0108 
subfamily J sequence contamination 
warning entry, partial (12%) 
AF130063 Homo sapiens clone FLB7723 39.7652 0.0109 
PR02055 mRNA, complete cds 
THC2178569 IL10 HUMAN (P22301) lnterleukin- 5.2657 0.0111 
10 precursor (IL-l 0) (Cytokine 
synthesis inhibitory factor) (CSIF), 
partial (7%) 
AK098257 Homo sapiens eDNA FLJ40938 fis, 2.8171 0.0113 
clone UTERU2007639 
ENST00000328398 Homo sapiens eDNA FLJ25433 fis, 4.1934 0.0116 
clone TST06506 
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BX397553 Homo sapiens PLACENTA COT 25- 91.8707 0.0124 
NORMALIZED Homo sapiens 
eDNA clone CSODI039YGO 1 3-
PRIME, mRNA sequence 
A 32 P212820 Unknown 1.6892 0.0124 
THC2131693 Unknown 4.6878 0.0126 
THC2098249 SET_ HUMAN (Q01105) SET protein 7.8556 0.0132 
(Phosphatase 2A inhibitor I2PP2A) (I-
2PP2A) (Template activating factor I) 
(TAF-I) (HLA-DR associated protein 
II) (PHAPII) (Inhibitor of granzyme 
A-activated DNase) (IGAAD), partial 
(66%) 
A 24 P920699 Unknown 30.0948 0.0141 
THC2136793 Unknown 4.0488 0.0145 
A 24 P255865 Unknown 2.4373 0.0147 
Up-regulated 
THC2120948 Unknown 0.1772 0.0003 
THC2122677 Q6P1A9 Ribosomal protein L7a, 0.3429 0.0003 
partial ( 11 %) 
CR610892 full-length eDNA clone 0.5257 0.0012 
CSODD006YA06 ofNeuroblastoma 
Cot 50-normalized of Homo sapiens 
(human) 
M84605 Human putative opioid receptor 0.3857 0.0017 
mRNA, complete cds 
A 24 P33403 Unknown 0.5920 0.0018 
THC2230645 Unknown 0.6478 0.0021 
AK025388 Homo sapiens eDNA: FLJ21735 fis, 0.4567 0.0026 
clone COLF3350 
BC066916 Homo sapiens eDNA clone IMAGE: 0.4099 0.0027 
4838452, partialcds 
THC2096438 GP20_HUMAN (Q99678) Probable 0.4451 0.0027 
G protein-coupled receptor GPR20, 
complete 
THC2138308 Unknown 0.5225 0.0029 
BX091213 Soares_ multiple_ sclerosis_ 2NbHMS P 0.2751 0.0031 
Homo sapiens eDNA clone 
IMAGp998H14631; IMAGE:284605, 
mRNA sequence 
AK092378 Homo sapiens eDNA FLJ35059 tis, 0.3937 0.0031 
clone OCBBF20 18827 
A 24 P917971 Unknown 0.3446 0.0044 
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AF229804 Homo sapiens endozepine-like protein 0.2297 0.0046 
type 2 mutant rnRNA, complete cds 
ENST00000354689 Myosin-reactive immunoglobulin 0.2961 0.0047 
heavy chain variable region 
(Fragment). [Source:Uniprot/ 
SPTRBMBL;Acc:Q9UL88] 
A 23 P89529 Unknown 0.3428 0.0050 
THC2097125 1207289A reverse transcriptase 0.2921 0.0050 
related protein. {Homo sapiens;}, 
partial (3%) 
BC063702 Homo sapiens eDNA clone IMAGE: 0.4259 0.0058 
4538703,partialcds 
N34499 N34499 yy55g04.sl Soares_ multiple_ 0.3576 0.0059 
sclerosis_ 2NbHMSP Homo sapiens 
eDNA clone IMAGE:277494 3' similar 
to contains Alu repetitive element; 
contains element MER9 repetitive 
element;, rnRNA sequence 
THC2063896 Unknown 0.1180 0.0063 
BX108468 Soares_testis_NHT Homo sapiens 0.4796 0.0067 
eDNA clone IMAGp998Jl44405, 
mRN A sequence 
AK057923 Homo sapiens eDNA FLJ25194 fis, 0.3382 0.0074 
clone RBC04095 
BC043523 Homo sapiens, clone IMAGE:5166551, 0.4064 0.0087 
mRNA 
A 24 P413286 Unknown 0.2731 0.0089 
BI490920 BI490920 dtDlalO.wl Morton Fetal 0.2011 0.0093 
Cochlea Homo sapiens eDNA clone 
IMAGE:2482074 3', mRNA sequence 
THC2186083 Unknown 0.6317 0.0093 
A 24 P84719 Unknown 0.4875 0.0102 
A 24 P930482 Unknown 0.1375 0.0110 
AK024371 Homo sapiens eDNA FLJ14309 fis, 0.5410 0.0112 
clone PLACE3000221 
A 32 Pl01019 Unknown 0.1235 0.0121 
THC2214096 Unknown 0.2751 0.0140 
*Fold change indicates pre-exercise intensity values divided by post-exercise values. 
:' 
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Chapter 4: Discussion 
4a: Candidate-gene association study 
Ghrelin has been recognized for its involvement in the coordination of energy 
balance and weight regulation, and while its dysregulation may be important in the 
etiology of obesity (Eisenstein and Greenberg, 2003), the roles of genetic variations in 
this gene on obesity in humans are still not clear. In the present study, we have 
investigated the association between three SNPs in the ghrelin precursor gene with body 
composition and serum lipids in a large population. The results of the current study do 
not support a significant role for genetic variations within the ghrelin precursor gene in 
the regulation ofbody composition or serum lipid profiles in the Newfoundland 
population. 
In the present study, the genetic association analyses were performed from three 
aspects. First, we determined if a difference in allele frequencies existed between lean 
and obese groups, while accounting for confounding factors, such as gender and age. 
Since it is the amount of body fat, rather than the amount of excess body weight, that 
determines the health risks of obesity (World Health Organization, 1998), we classified 
our cohort according to adiposity (%BF, %LF, and %TF) using DXA, which is one of the 
best methods for the determination of body composition (Prior et al., 1997). Also, as a 
comparison, we classified our subjects according to BMI, which is known to provide an 
estimation of adiposity. The sole use of BMI, a field method, in analyses will introduce 
unreliability into reported findings. In the present study, for instance, we found a large 
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difference when classifying our subjects as obese and non-obese according to BMI and 
%BF using DXA. When females were classified according to %BF, 49% of subjects 
were considered lean and 51% were obese, while according to BMI, 72% were classified 
as lean and only 28% as obese. A very similar misclassification also occurred for males 
as well, thus indicating that BMI is not a reliable classification method of body 
composition for analyses in association studies of this type. Upon analysis of our results, 
we found no significant differences of allele frequencies for any SNP investigated 
between the lean and obese groups when classified according to %BF, %TF, %LF, or 
BMI. 
The second type of analysis investigated whether a genotype effect existed; that is, 
whether a certain genotype was associated with significantly different body composition 
(%BF, %TF, %LF, and BMI) or serum lipid parameter. Although not statistically 
significant, a trend was observed in males whereby the GG genotype of Exon 1 had 
higher body fat and as well the G allele appeared to associate with higher levels ofTGs 
and lower levels HDL-C. The polymorphism locate in Exon 1 would have the greatest 
"potential" of affect functioning ghrelin levels. This polymorphism results in an amino 
acid substitution in the pre- or pro- portion of the ghrelin peptide and thus may potentially 
affect further processing, such as proteolytic cleavage or acylation in this case. It is 
interesting, despite not being statistically significant (possibly related to sample size), that 
males homozygotes for the GG genotype tended to have a greater likelihood of being 
obese and a poorer lipid profile. Lastly, in addition to allele and genotype associations, 
we also investigated haplotype associations, since it has been suggest that the 
determination ofhaplotypes, or combinations of SNPs, that are in linkage disequilibrium 
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may offer more power to detect associations than simply measuring individual SNPs 
(Drysdale eta!., 2000). In agreement with our other results, we found that no significant 
difference existed between the different haplotype groups for body composition or for any 
serum lipid parameter. 
The current status of genetic association studies on GHRL has indicated that SNP 
346G-7 A, which leads to the replacement of arginine with glutamine at amino acid 51 of 
the preproghrelin sequence (amino acid 28 of the mature peptide), was associated with 
obesity in the Swedish population (Ukkola eta!., 2001). They discovered that the 
arg51 gln mutation, in heterozygote form, was found in 6 of the 96 severe obese female 
subjects, but not among the 96 non-obese female control subjects (p<0.05). The 
association between the arg51 gln polymorphism and obesity, however, could not be 
confirmed by this group using a larger cohort (Ukkola eta!., 2002) or by another group 
using a German cohort (Hinney eta!., 2002). In the present study, it should be noted that 
the three SNPs investigated did not correspond to amino acid alterations within the 
mature ghrelin protein. However, a previous study has shown that children carrying the 
SNP 408C-7 A, which leads to the substitution of leucine for methionine at amino acid 72 
of the preproghrelin sequence, had significantly higher BMI and an earlier age of obesity 
onset compared to those children carrying only the wildtype allele (Korbonits eta!., 
2002). 
In summary, since no significant difference existed between the allele, genotype, 
or haplotype groups for any SNP investigated for body composition (after accounting for 
gender and age) or for any serum lipid parameter (after accounting for gender, age, and 
%BF), the results suggest no relationship exists. Thus, the results of the present study do 
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not support a significant role for genetic variations within the ghrelin precursor gene in 
the regulation ofbody compositions and serum lipid profiles in the NL population. 
Furthermore, since candidate gene association studies have been questioned because of 
non-replication of results, in part due to small sample size and over-interpretation of data, 
our study demonstrated a comprehensive study design whereby these factors were 
minimized. 
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4b: Changes in adipose tissue gene expression in response to short-term aerobic 
exercise 
The most common and detrimental metabolic diseases affecting over 50% of the 
adult population are obesity and its associated metabolic pathologies (Wellen and 
Hotamisligil, 2003). The present study investigated the differential global mRNA 
expression profiles of abdominal subcutaneous adipose tissue of lean and obese males, in 
response to a 7-day aerobic exercise protocol (60% V02 max), using long oligonucleotide 
whole human genome microarrays. All individuals in the present study were males and 
within a narrow age range in an effort to reduce the effects of gender and age on the 
global mRNA expression patterns. 
We also investigated the effect of aerobic exercise on body composition and 
biochemical parameters in lean and obese men. We found that the response to short-term 
aerobic exercise differed in lean and obese subjects. Obese subjects, for instance, 
significantly decreased their percentage of trunk fat after the exercise protocol. 
Furthermore, triglyceride levels also showed a similar decreasing trend (p = 0.07). Lean 
individuals, on the other hand, did not experience similar changes, despite being exposed 
to the same intensity exercise regimen. Other studies have also reported similar results 
whereby obese individuals experienced a significant reduction in abdominal fat in 
response to aerobic exercise (:S 70% V02 max) without a corresponding change in BMI 
(Ross et al., 2000;Ross eta!., 2004). Another study reported that, following a prolonged 
exercise intervention, the bodyweight of obese children significantly decreased, while the 
normal- weight control group actually gained weight, possibly due to an increase in lean 
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body mass (Hayashi eta!., 1987). Responses to exercise interventions, however, often 
vary considerably between individuals, and previous research has indicated that the 
response to exercise may be significantly affected by genetic components (Bouchard et 
al., 1999). Consequently, the main goal of the present study was to investigate the 
molecular genetic basis of metabolic routes within abdominal subcutaneous adipose tissue 
of obese and lean men in response to exercise through the analysis of global mRNA 
expression patterns. It should be realized, however, that not all differentially expressed 
genes result in a functional effect. Also, some differentially expressed genes are a result 
of secondary affects due to the obese state. These genes are difficult to distinguish and 
other methodologies, such as animal studies and in vitro studies, are needed to help 
clarify this issue. This is beyond the scope of the present thesis. 
4b.l: Changes in gene expression as a response to short-term aerobic exercise in 
obese men 
Regular physical activity is known to contribute to the cure of obesity-associated 
metabolic diseases (Richterova eta!., 2004), and it appears to be one of the major factors 
determining the long-term success of weight loss (Pavlou eta!., 1989). One possible 
explanation for this observation may stem from the fact that regular physical activity 
protects against diseases characterized by chronic, low-grade systemic inflammation 
(Petersen and Pedersen, 2005), such as obesity (Das, 2001 ;Festa et al., 2001; Weyer et a!., 
2002;Bullo eta!., 2003). It has been shown that circulating levels of several markers of 
inflammation, including pro-inflammatory cytokines and acute-phase proteins such as 
tumor necrosis factor-alpha (TNF-a), interleukin-6 (IL-6), C-reactive protein (CRP), and 
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secretory phospholipase A2 (sPLS2), are elevated in obese persons. Pro-inflammatory 
cytokines refer to low molecular weight (8,000 to 40,000 dalton) proteins that promote 
inflammation, whereas cytokines that suppress the activity of proinflammatory cytokines 
are referred to as anti-inflammatory cytokines (Dinarello, 2000a). Obesity is also 
believed to be a consequence of inflammatory disease, and not vice-versa (Das, 2001 ). 
Moreover, the inflammatory response associated with obesity is thought to be triggered 
by, and reside mainly within, adipose tissue (Wellen and Hotamisligil, 2003). 
In obese samples in our study, gene ontology analysis indicated a significant 
enrichment ofup-regulated genes in sphingolipid metabolism and ceramide metabolism 
in response to aerobic exercise. Because TNF -a and inter1eukin-l (IL-l) utilize the 
sphingomyelin pathway, it has been suggested that this signalling pathway is used in 
inflammation and immune responses (Kolesnick and Golde, 1994;Huwiler eta!., 1996), 
but its role has not been extensively studied with respect to obesity. The sphingomyelin 
pathway is an evolutionarily conserved, ubiquitous signalling system that is initiated by 
the hydrolysis of sphingomyelin, a plasma membrane phospholipid (Pena eta!., 1997). 
The phosphodiester bond of sphingomyelin is hydrolyzed by acid and neutral 
sphinogmyelinase isoforms generating ceramide and phosphocholine. Ceramide serves as 
a second messenger of this pathway by interacting with a number of direct targets 
including, ceramide-activated protein kinase (CAPK) (Mathias eta!., 1991 ), ceramide-
activated protein phosphatase (CAPP) (Dobrowsky and Hannun, 1993), and protein 
kinase C~ (PKC~) (Muller eta!., 1995). As well, ceramide interacts with several 
signalling systems, such as mitogen-activated protein kinase (MAPK), Jun kinase (JNK), 
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caspase, and mitochondrial signalling systems, which affect numerous cellular functions, 
including proliferation, differentiation, growth arrest, and death (Mathias eta!., 1998). 
Furthermore, in response to diverse stresses, mammalian systems generate ceramide 
through rapid activation of neutral and acidic sphingomyelinases (Hannun eta!., 2001 ), 
and signalling through ceramide appears to play a role in the development of human 
diseases, including insulin resistance associated with obesity and diabetes (Mathias et a!., 
1998). Our results indicated that within the subcutaneous adipose tissue of obese men 
there was nearly a 12-fold decrease in the expression of neutral sphinogmyelinase 2 (also 
known as sphingomyelin phosphodiesterase 3, SMPD3) in response to acute aerobic 
exercise. It has been reported that neutral sphinogmyelinase 2 is one of the key enzymes 
involved in ceramide generation, and that it is a TNF-responsive enzyme that plays an 
important role in the regulation of sphingomyelin metabolism (Marchesini et al., 2003 ). 
It has also been reported that prolonged exercise of moderate intensity leads to reduced 
levels of ceramide in both fast-twitch red and slow-twitch red rat muscle, along with a 
corresponding decrease in neutral sphinogmyelinase activity (Dobrzyn and Gorski, 2002). 
To our knowledge, this is the first study to show a decrease in the expression of SMPD3 
within the subcutaneous adipose tissue of obese individuals in response to aerobic 
exercise. A down-regulation of SMPD3 expression suggests a possible decrease in 
ceramide generation. Ceramide is known to affect many cell types and tissues with a 
wide range of effects, however, most research has focused on its role in apoptosis 
(Mathias et al., 1998). For instance, ceramide has been observed to bind and activate 
protein kinase c-Rafin rat mesangial cells, which subsequently leads to the activation of 
the MAPK cascade, which signals inflammation (Huwiler et al., 1996). In 3T3-Ll 
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adipocytes, ceramide caused a similar effect to that ofTNF-a in down-regulating the 
glucose transporter GLUT4 and impeding glucose uptake (Long and Pekala, 1996). This 
is a similar situation that often appears in the subcutaneous adipose tissue of obese 
individuals (Garvey et al., 1991 ). Thus, it appears that the subcutaneous adipose tissue of 
obese individuals may respond to aerobic exercise by decreasing the amount of ceramide, 
which, in turn, may alleviate its harmful effects. Ceramide, however, can also be 
phosphorylated to ceramide-1-phosphate (ClP) by ceramide kinase (CERK) (Sugiura et 
al., 2002). Obese individuals in our study experienced nearly a 2-fold increase in the 
expression of CERK in response to aerobic exercise. It has been shown that C 1 P is 
located mainly in the neutrophil plasma membrane and that it promotes phagolysosome 
formation, a critical event in phagocytosis (Hinkovska-Galcheva et al., 1998). It has also 
been demonstrated that in fibroblasts CIP stimulates DNA synthesis, but does not alter 
the phosphorylation state ofMAPK (Gomez-Munoz et al., 1997). Furthermore, it is 
believed that the conversion of ceramide to C 1 P may serve as a mechanism to terminate 
the proapoptotic actions of ceramide (Sugiura et al., 2002). Thus, an increase in CERK 
expression may increase the conversion of ceramide to C 1 P, which may, in turn, further 
decrease the levels of ceramide. We also found 2 other genes differentially regulated in 
obese individuals with roles in ceramide metabolism. The expression ofASAH2 (N-
acylsphingosine amidohydrolase 2) was decreased 2-fold in response to exercise, while 
the expression of ST3GAL5 (ST3 f)-galactoside a-2,3-sialyltransferase 5) was increased 
nearly 2-fold. The functions of both ASAH2 and ST3GAL5, however, have not been 
extensively studied with respect to ceramide metabolism. Taken together, it appears that 
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the abdominal subcutaneous adipose tissue of obese individuals respond to short-term 
aerobic exercise through the regulation of the ceramide/sphingomyelin pathway, possibly 
to reduce the harmful inflammatory effects of ceramide. 
The regulation of sphingomylinases has also been linked to several cell surface 
receptors, including the interleukin-1 receptor (Mathias et al., 1993 ). It is interleukin 1 
receptor, type 1 (ILIRI), and not interleukin 1 receptor, type II (ILIRII), which is the 
signal-transducing receptor upon which IL-l binds (Dinarello, 2000a). It is known that 
many cell types release IL-l when exposed to an inflammatory environment (Huwiler et 
a!., 1996). IL-l is a cytokine that stimulates the production of highly inflammatory 
substances, such as prostaglandins and nitric oxide, as well as promoting the synthesis of 
small proteins that aid in the entry of neutrophils, macrophages, and lymphocytes into 
tissues (Dinarello, 2000b ). It is believed that the increased production of IL-l that 
accompanies human inflammatory diseases contributes to the pathologic process 
following binding to its receptor. Thus, it has been suggested that administering agents 
that reduce the effects ofiL-1 should improve inflammatory diseases. However, it is 
believed that the IL-l-mediated disease severity is regulated at the level of ligand 
production and activity, and not at the receptor level (Dinarello, 2005). It is known that 
type 1 IL-l receptors are only increased 2- or 3-fold in the disease state, whereas IL-l is 
increased over 100-fold. We found that in obese individuals there was nearly a 2-fold 
increase in expression of ILl Rl in response to aerobic exercise, with no significant 
change in IL-l expression. Since IL-l-mediated disease severity is not regulated at the 
receptor level, it is difficult to evaluate the effect of a possible increase in IL 1 R 1 in 
response to aerobic exercise. It has been previously reported, however, that physical 
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activity in obese individuals elicits a temporary inflammatory response with elevated 
plasma levels of IL-l, but not elevated IL- I gene expression levels in blood mononuclear 
cells (Moldoveanu et a!., 2000). 
It is known that human adipose tissue expresses a local renin-angiotensin system 
that includes angiotensinogen, angiotensin converting enzyme (ACE), renin, and the type 
1 angiotensin receptor (Schling eta!., 1999). Angiotensin II, the activation product of 
angiotensinogen, is a vasopressor hormone that regulates blood pressure and volume 
through its interaction with type 1 angiotensin II receptors (Murphy eta!., 1991 ). 
Angiotensin II, however, is also a proinflammatory peptide, and it has been suggested that 
the obstruction of its action by an angiotensin receptor blocker will likely exert an anti-
inflammatory action (Phillips and Kagiyama, 2002). We found that the expression of 
AGTRI (angiotensin II, type 1) was up-regulated nearly 5-fold in obese individuals after 
exercise. An increase in AGTRI expression is likely to lead to an increase in angiotensin 
II receptor levels. An increase in receptor levels increases the possibility of angiotensin II 
exerting an inflammatory action, however, we did not find an increase in the expression 
of angiotensinogen or ACE. Thus, it is difficult to determine the net effect of an increase 
in the expression of A GTRI. 
Physical activity is also known to promote the activation of the sympathetic 
nervous system (SNS) as well as increase the levels of circulating catecholamines (Galbo 
eta!., 1975;Christensen and Galbo, 1983). Catecholamines (epinephrine and 
norepinephrine) activate the lipolytic cascade through their interaction with~­
adrenoceptors (~ 1 , ~2 , and ~ 3 ), G-protein-coupled receptors, on the plasma membrane of 
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adipocytes (Horowitz, 2003). Catecholamines interaction with a 2-adrenoceptors, on the 
other hand, inhibits lipolytic activity. Upon the binding of catecholamines to the~­
adrenoceptors, an activated complex is formed with a stimulatory G protein (Gs), and this 
complex is responsible for the activation of adenylate cyclase, which is responsible for 
the increase in the concentration of cyclic adenosine monophosphate (cAMP), and 
consequently the activation of cAMP-dependent protein kinase (PKA) (Lange, 2004) 
(Figure 4.1). The holoenzyme ofPKA is a tetrarner of2 regulatory and 2 catalytic 
subunits (Orstavik eta!., 2005). PKA activation occurs upon the binding of 2 cAMP 
molecules to each regulatory subunit, which results in a conformational change that 
releases the active catalytic subunits. PKA is responsible for the phosphorylation of 
hormone sensitive lipase (HSL), generally though to be the rate-limiting enzyme, as well 
as perilipin, a lipid droplet surface protein (Tansey et al., 2004). Our results indicate that 
in obese individuals there is over a 6-fold decrease in the catalytic alpha subunit of PKA 
(PRKACA) expression in response to acute aerobic exercise. The vital role of PKA, 
especially the catalytic alpha subunit, has previously been demonstrated. It was shown 
that a null mutation in the catalytic alpha subunit of PKA, which is the major catalytic 
subunit, lead to early postnatal lethality in the majority of the Ca knockout mice 
(Skalhegg eta!., 2002). Thus, due to the fact that the alpha catalytic subunit is the major 
catalytic subunit ofPKA, it is likely that there is a decrease in the phosphorylation of 
HSL and perilipin in obese individuals. Since an increase in PKA phosphorylation of 
HSL and the perilipins is known to cause a dramatic increase in lipolysis (Holm, 2003), it 
is plausible that obese individuals have a decreased rate of lipolysis in response to acute 
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Figure 4.1 The activation of the lipolytic cascade through the interaction of 
catecholamines with the ~-adrenoceptor (Horowitz, 2003). 
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aerobic exercise. To our knowledge, this is the first study to demonstrate that the 
expression of PRKACA is down-regulated in obese men in response to aerobic exercise. 
This result is also consistent with a previous study that demonstrated in males that the 
lipolytic response to exercise decreases with increasing adiposity (Mittendorfer eta!., 
2004). They claim that the decrease in lipolytic rate limits the availability of plasma fatty 
acids as a fuel during exercise. We, however, also found that obese individuals have an 
up-regulation of a fatty acid transporter (SLC27A6) by nearly 2-fold. The up-regulation 
of SLC27 A6 might serve as a compensatory response to the reduced lipolytic rate or the 
increased demand on fatty acids during exercise. The actual role ofHSL, however, in the 
lipolysis pathway is that, when phosphorylated, it moves from the cytosol of the 
adipocyte to the surface of the lipid droplet, where phosphorylated perilipin A permits 
access to intracellular TGs, so that efficient TG hydrolysis can occur (Sztalryd eta!., 
2003) (Figure 4.1). It is, however, adipose triglyceride lipase (ATGL), rather than HSL, 
that predominantly hydrolyzes the first ester bond ofTGs (Zimmermann eta!., 2004). 
HSL cleaves TGs as well as diglycerides (DGs), however, its specific activity for DGs is 
10 fold that for TGs (Fredrikson eta!., 1981). Thus, it is both ATGL and HSL that 
catabolize stored TGs in adipose tissue of mammals (Zimmermann eta!., 2004). In our 
case, if the phosphorylation of HSL and perilipin were decreased, the rate of movement of 
phosphorylated HSL from the cytosol to the surface would be decreased, as would its 
access to TGs for hydrolysis. 
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4b.2: Changes in gene expression as a response to short-term aerobic exercise in lean 
men 
In response to short-term aerobic exercise, lean individuals seem to regulate 
lipolysis at a number oflevels. For instance, there appears to be regulation at the level of 
cAMP. We found that, in response to exercise, lean individuals had a down-regulation of 
adenylate cyclase 6 (ADCY6) expression by nearly 5-fold. Adenylate cyclase 6 is a 
membrane-associated enzyme that catalyzes the formation of cAMP. Thus, it appears 
that exercise may lead to a decreased level of cAMP, which could potentially lead to a 
decrease in the rate of lipolysis. However, we also report that lean individuals had an up-
regulation of expression of adenylate cyclase activating polypeptide 1 (ADCYAP 1), a 
gene that appears in the 2004 human obesity gene map (Perusse et al., 2005), by 
approximately 2-fold. The encoded protein of ADCYAP 1 stimulates adenylate cyclase 
and subsequently increases the level of cAMP. Thus, an up-regulation of this gene will 
likely increase the level of cAMP. Taken together, both ADCY6 and ADCY AP 1 may 
possibly work in unison to regulate the level of cAMP, and consequently possibly 
regulate the rate oflipolysis. Another level of regulation appears to be by protein 
phosphatase-! (PP 1) at the surface of the lipid droplet. PP 1 is a serine/threonine-specific 
protein phosphatase involved in the dephosphorylation of numerous proteins, and work in 
opposition to the protein kinases to control the level of phosphorylation. PP 1 has 3 
catalytic subunits: alpha, beta (also known as delta), and gamma. It has been shown that 
the dephosphorylation ofperilipin in adipocytes is mediated through PPl (Clifford eta!., 
1998). Dephosphorylated perilipin would deny access of HSL to intracellular TGs, and 
thus have an anti-lipolytic effect. We report that, in response to exercise, lean individuals 
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had nearly a 4-fold decrease in the mRNA for protein phosphatase 1, catalytic subunit, ~ 
isoform (P P PI CB). Consequently, it appears that the down-regulation of P P PI CB will 
likely have a lipolytic effect. The expression of PPP I CB may serve as another point of 
regulation for lipolysis. To our knowledge, this is the first finding that PPP I CB 
expression is down-regulation in lean individuals in response to aerobic exercise. This 
finding is also in agreement with the notion that the surface of the lipid droplet is a central 
site of regulation of lipolysis (Tansey eta!., 2004). There also appears to be regulation at 
the TG level via acyl-CoA:diacylglycerol acyltransferase 2 (DGAT2; also known as 
diacylglycerol 0-acyltransferase homolog 2). DGAT2 has been recognized as a second 
mammalian DGAT with high expression in white adipose tissue, which is responsible for 
the final step in TG synthesis and believed to play a significant role in mammalian TG 
metabolism (Cases et al., 2001). A recent gene knockout study in mice (Dgat2_1_) 
demonstrated that DGAT2 is the DGA T responsible for the majority of triglyceride 
synthesis and that DGAT2 is required for survival (Stone et al., 2004). DGAT2-deticient 
mice were reported to be lipopenic, with severely reduced triglyceride content in their 
tissues. Furthermore, since it has been reported that the tissue expression pattern of 
DGAT2 in mice is similar to that in humans (Cases eta!., 2001 ), it is suggested that 
DGAT2 plays a similar essential role in triglyceride metabolism in humans (Stone eta!., 
2004). Lean individuals in our study, in response to exercise, experienced an up-
regulation of DGAT2 expression by approximately 3-fold. Thus. it is possible that the up-
regulation of DGAT2 will lead to a rise in TG synthesis and thus an increase in the 
availability ofTGs for hydrolysis. Furthermore, it is possible that the up-regulation of 
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DGAT2 when lipolysis is up-regulated serves as a protective function against the 
accumulating free fatty acids inside the cells. Free fatty acids can behave like detergents. 
However, we also report a down-regulation of very low-density lipoprotein receptor 
(VLDLR) expression by approximately 4-fold. VLDLR is known for its involvement in 
the delivery of fatty acids to the adipose tissue and building of adipocyte TG stores 
(Tacken et al., 2001). Thus, a decrease in the expression of VLDLR might decrease the 
availability ofTGs for hydrolysis. The down-regulation of VLDLR, however, might be an 
indictor of a reduced availability ofTGs in circulation. Nevertheless, it is possible that 
DGAT2 and VLDLR work in concert to regulate the level ofTGs available for 
hydrolysis, and consequently potentially regulate the rate of lipolysis. In this case, the 
rate oflipolysis in lean individuals in response to exercise is likely increased. Many other 
studies have demonstrated that the increased energy demands of the body during physical 
activity are met, in part, by an increased rate oflipolysis in adipose tissue (Wolfe et al., 
1990;Klein et al., 1994;Horowitz eta!., 1997;Stich and Berlan, 2004). 
In lean individuals, in response to exercise, there seemed to be regulation of the 
insulin-signalling pathway through protein tyrosine phosphatases (PTPs). PTPs are 
involved in many cell-signalling systems, whereby they serve to dephosphorylate tyrosine 
residues of proteins (Stoker, 2005). Two main classes of PTPs are the classical receptor 
PTPs and the classical non-receptor PTPs. The PTPs that have been implicated in the 
dephosphorylation of the insulin receptor (IR) have received growing attention in the field 
of type 2 diabetes and obesity, since their inhibition would be expected to prolong insulin 
signalling and thereby facilitate glucose uptake, and in tum, lower blood glucose (Asante-
Appiah and Kennedy, 2003). For instance, it was demonstrated that PTP I B knockout 
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mice were resistant to weight gain and remained insulin sensitive on a high-fat diet, while 
the wild-type mice rapidly gained weight and became insulin resistant (Elchebly eta!., 
1999). It has been suggested that the loss ofPTPlB specifically in the adipose tissue of 
the PTP I B knockout mice is a contributing factor for the observed obesity resistance 
(Asante-Appiah and Kennedy, 2003). Another PTP that has been implicated in the 
insulin-signalling pathway and the dephosphorylation of IRis SHP2 (also known as 
PTPNll), which falls into the non-receptor class. It has been shown that expression of 
SHP2 in a transgenic mouse model lead to an insulin-resistant phenotype, thus indicating 
that it is a negative modulator of insulin signalling (Maegawa eta!., 1999). In our study, 
there was a 3-fold decrease in expression of PTPNI I (SHP2) in lean individuals in 
response to exercise. Furthermore, there was a decrease in the expression of 2 other 
PTPs, one falling into the receptor class, PTP RD ( 10-fold decrease), and the other falling 
into the non-receptor class, PTPN3 (2-fold decrease). Despite limited research on 
PTPRD and PTPN3, it is suggested that a wide range of PTPs could dephosphorylate IR 
and significantly influence the level of insulin signalling (Stoker, 2005). To our 
knowledge, this is the first study to reveal a decrease in the expression of PTPs in the 
abdominal subcutaneous adipose tissue of lean individuals in response to aerobic 
exercise. A possible decrease in the level of PTPs could potentially enhance insulin 
sensitivity and enable the facilitation of glucose uptake during exercise in lean 
individuals. This hypothesis is consistent with the fact that physical exercise, via 
mechanisms not fully clear, increases muscle glucose uptake, enhances post-exercise 
insulin sensitivity and leads to fatty acid oxidation in muscle (Fujii eta!., 2004). 
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Another interesting gene that we found up-regulated ( 4-fold) in the subcutaneous 
adipose tissue of lean individuals in response to aerobic exercise was peroxisome 
proliferative activated receptor, alpha (PPARA), a gene which appears in the 2004 human 
obesity gene map (Perusse et a!., 2005). PP ARA, along with 2 other subtypes of PP AR, 
G (gamma) and D (delta), belong to the superfamily of nuclear hormone receptors 
(Berger and Moller, 2002). PP ARs are lipid sensors that serve as transcriptional 
regulators of numerous genes involved in nutrient metabolism and energy homeostasis 
(Berger eta!., 2005). The crucial role of PP ARA in energy homeostasis has been shown 
in PPARA null mice, which are characterized by hyperlipidemia, hypoglycermia, 
hypoketonimia, and hepatic steastosis upon fasting (Kersten eta!., 1999). A mutation 
(L162V) within PPARA has also been associated with reduced body fat percentage and 
BMI (Bosse et al., 2003). Furthermore, since it has been shown that PPARA agonists 
decrease TG levels and increase HDL-C levels (Linton and Fazio, 2000), a possible 
increase in PPARA levels in lean individual in response to exercise may exert a similar 
effect to meet the increased demand ofthe body for fuel. Another gene in the PPAR gene 
family, which also appears in the 2004 human obesity gene map, is PP ARG co-activator 1 
(PPARGCJA) (Perusse et al., 2005). Polymorphisms within this gene are associated with 
total body fat, BMI, and waist and hip circumferences (Esterbauer et al., 2002). 
Furthermore, it has been shown that PGCl-alpha (also known as PPARGClA) null mice 
were lean and resistant to diet-induced obesity, thus indicating an important role for 
PGC 1-alpha in the control of energy metabolism (Lin et al., 2004 ). We report the down-
regulation (2-fold) of peroxisome proliferative activated receptor, gamma, coactivator-
related 1 (PPRCJ) in lean individuals in response to exercise. Although the biological 
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function of PPRC 1 is still not clear, it is likely that it has a similar function to that of 
PP ARG co-activator 1. To our knowledge, this is the first finding of the differential 
expression of PPARA and PPRCJ in lean individuals in response to aerobic exercise. 
Taken together, in response to exercise, the differential regulation of PP ARA and PPRC 1 
may function to favourably control energy metabolism in lean individuals. 
Interestingly, in lean individuals in response to exercise there appeared to be a 
decrease in the generation of adenosine triphosphate (ATP) within the abdominal 
subcutaneous adipose tissue. We report a down-regulation of mitochondrial aconitase 2 
(A C02) expression by 2-fold. Mitochondrial aconitase catalyzes the conversion of citrate 
to isocitrate within the tricarboxylic acid (TCA) cycle. Inhibition of aconitase is known 
to divert metabolism from energy production to fat synthesis (Wlodek and Gonzales, 
2003). The down-regulation of A C02 in lean individuals may possibly aim to restore the 
amount ofTGs that were mobilized during exercise. Also, it is possible that, since TG 
synthesis requires more energy from ATP than lipolysis, an adaptation to a new steady 
state is occurring within the adipocytes where there is less TG synthesis compared with 
lipolysis. Less energy (ATP) is needed so fewer enzymes in A TP generating pathways 
are required and thus less mRNA for these enzymes are produced. 
4b.3: A comparison of lean and obese individuals in their genome-wide expression 
response to short-term aerobic exercise 
The first major difference that existed between lean and obese individuals in 
response to aerobic exercise was that the differential regulation of genes involved in 
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inflammation was unique to the subcutaneous adipose tissue of obese individuals. This 
finding is consistent with previous literature since obesity is associated with chronic, low-
grade systemic inflammation. We found that within the abdominal subcutaneous adipose 
tissue of obese individuals, in response to acute aerobic exercise, there was nearly a 12-
fold decrease in the expression of SMPD3 as well as a 2-fold increase in the expression of 
CERK, which likely lead to a reduction in the levels of ceramide. We also found the 
differential regulation of other genes involved in ceramide metabolism (ASAH2 and 
ST3GAL5), as well as other genes associated with inflammation (ILIRJI and AGTRI). 
Since this is the first study, to our knowledge, to find the differential regulation of these 6 
inflammatory related genes within the abdominal subcutaneous adipose tissue in response 
to aerobic exercise, it provides insight into the mechanisms of inflammation associated 
with the obese state. 
The second difference that existed between lean obese individuals in response to 
aerobic exercise was the regulation of lipolysis. In obese individuals, our results 
indicated a likely decrease in the rate of lipolysis in response to exercise. Obese 
individuals experienced a 6-fold decrease in PRKACA expression, which likely lead to a 
decrease in the phosphorylation ofHSL and the perilipins, as well as a compensatory 2-
fold increase in the expression of SLC2 7 A6 to the reduced lipolytic rate or the increased 
demand on fatty acids. Lean individuals, on the other hand, experienced a tight 
regulation oflipolysis at several different levels with a possible increase in rate. There 
was regulation at the cAMP level with ADCY6 and ADCY AP 1, regulation at the surface 
of the lipid droplet via dephosphorylation of perilipins by PPP 1 CB, and regulation at the 
triglyceride level by DGAT2 and VLDLR. The likely decrease in the rate of lipolysis in 
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obese individuals, despite aerobic exercise training, suggests a genetic basis of 
impairment in lipolysis regulation. However, it has been suggested that obese subjects 
who show impairments in the regulation of lipolysis could have their impairment 
corrected by dietary intervention (Stich and Berlan, 2004). To our knowledge, this is the 
first study to indicate that the differential regulation of numerous genes in the lipolytic 
pathway may be the molecular explanation for the differences in the regulation of 
lipolysis in response to aerobic exercise that exists between lean and obese individuals. 
The third main difference that existed in our subjects in response to aerobic 
exercise was the down-regulation of protein tyrosine phosphatases within the abdominal 
subcutaneous adipose tissue of lean individuals. Since the significant down-regulation of 
PTPs were not observed in obese individuals, this indicates that the beneficial effect of 
exercise on insulin sensitivity in obese individuals may not go through the PTPs linked 
pathway. To our knowledge, this is the first study to provide a possible explanation of 
why insulin sensitivity is improved in lean individuals compared to obese individuals 
through the differential regulation of genes in the PTP pathway (PTPNIJ, PTPRD, and 
PTPN3). Furthermore, given that PTPs play a role in the regulation of the insulin-
signalling pathway, they may represent potential pharmacological targets in insulin-
resistant obesity. 
The fourth major difference between lean and obese individuals was the 
differentially regulation of peroxisome proliferative activated receptors in response to 
aerobic exercise within the lean. Since it is believed that the modulation ofPPAR activity 
might serve as an effective treatment for maladies associated with obesity (Berger et al., 
2005), and given the fact that obese individuals become fatigued faster than lean 
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individuals during physical exercise (Mattsson eta!., 1997), the differential regulation of 
PPARA and PPRCI may function to favourably control energy metabolism in lean 
individuals, while not in obese. To our knowledge, this is the first study to indicate that 
the differential regulation of PPARA and PPRCI, and, although only speculation, it may 
provide the molecular explanation of why obese individuals are more prone to fatigue 
during physical activity. 
101 
Chapter 5: Concluding remarks 
Obesity rates among Canadian children and adults have increased dramatically 
during the past 25 years (Statistics Canada, 2005). For instance, obesity rates have tripled 
for adolescents aged 12 to 17 and doubled for adults aged 25 to 34. The obesity epidemic 
is of great concern for the health and well being of many Canadians, especially in 
Newfoundlanders and Labradoreans where the prevalence of obesity is significantly 
higher than the national average. 
The current study has utilized two very different approaches to study the genetic 
factors that are involved in the common form of obesity. First, we have used the 
candidate gene association study approach to determine if the ghrelin precursor gene was 
associated with obesity phenotypes in the Newfoundland and Labrador population. The 
ghrelin precursor gene has been considered a genetic culprit involved in obesity, as it 
appears in the 2004 human obesity gene map (Perusse eta!., 2005). We have 
demonstrated that genetic variants within the ghrelin precursor gene do not appear to have 
a significant association with obesity phenotypes in the Newfoundland and Labrador 
population. Second, we have used microarray technology to simultaneously quantitate 
whole human genome mRNAs from abdominal subcutaneous adipose tissue of lean and 
obese young men to provide a comprehensive assessment of expression level in response 
to a 7-day aerobic exercise protocol. This particular study generated an enormous amount 
of data, which was deciphered using a number of methods. First, strict inclusion criteria 
were set to demonstrate significant expression changes in lean and obese samples in 
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response to exercise. Second, bioinformatic tools, such as gene ontology and systemic 
pathway analysis, were used to reveal the most relevant genes and pathways. 
The current microarray expression study has numerous important discoveries in 
terms of the gene expression patterns and differences between obese and lean subjects. 
First, our data were consistent with previous reports that indicate inflammatory pathways 
are involved in obesity, and we demonstrated that aerobic exercise might reduce the 
effects of inflammation through the regulation ofthe ceramide/sphingomyelin pathway, 
with a possible reduction in the level of ceramide within the abdominal subcutaneous 
adipose tissue. To our knowledge, this is the first study to demonstrate the likely 
reduction of ceramide levels within the subcutaneous adipose tissue of obese men in 
response to aerobic exercise. Secondly, we also found that the decrease in the rate of 
lipolysis in response to acute aerobic exercise in obese individuals is probably through the 
dephosphorylation ofHSL and perilipin by the down-regulation of PRKACA. Thirdly, 
our results indicated that short-term aerobic exercise in lean individuals might alter the 
insulin-signalling pathway through the regulation of protein tyrosine phosphatases, and 
that lean individuals might benefit from exercise by energy metabolism control through 
the differential regulation of the peroxisome proliferative activated receptors. Moreover, 
our findings provide insight into the role that physical exercise plays in contributing to 
controlling obesity by revealing possible mechanistic pathways that may be involved. As 
well, our study revealed numerous novel genes that warrant further research in the field of 
obesity and exercise physiology. In the future, these genes may serve as potential novel 
drugable targets, which may be invaluable to help against the global epidemic of obesity. 
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Chapter 6: Limitations of the present research 
6.1: Candidate-gene association study 
1) Although 1182 subjects is a reasonable number to perform association 
analyses, a second cohort would be ideal to replicate our findings. 
6.2: Genome-wide expression study of adipose tissue in response to acute aerobic 
exercise using microarray technology 
1) The sample size of this study was small (5 lean and 5 obese males) due to the 
high cost of the microarrays, as well as the invasiveness of the adipose tissue 
biopsy. 
2) The current obesity candidate genes identified from this study were obtained 
from the subcutaneous adipose tissue. Genes with tissue specific expression, 
such as in the liver and the skeletal muscle, may offer a more complete picture 
of the mechanisms involved in obesity. 
3) The current study investigated only males. The regulation of certain genes 
and pathways may be gender specific, thus an investigation into females is 
imperative. 
4) The current study investigated only a very narrow age range (20 to 27 years). 
Since the regulation of certain genes and pathways may be age specific, it is 
necessary to study other age ranges. 
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5) Since transcript levels do not always correlated with protein abundance levels, 
and given that cellular functions are generally carried out by proteins, future 
studies need to address the involvement of different metabolic pathways using 
protein arrays or other proteomic methods. 
6) The present study only investigated abdominal subcutaneous adipose tissue, 
and thus we cannot conclude that these data are representative of other adipose 
tissue depots in the body. 
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Chapter 7: Future plans 
7.1: Candidate-gene association study 
1) An independent family-based association study is in progress, and will 
eventually serve as a second cohort to replicate our findings. 
7.2: Genome-wide expression study of adipose tissue in response to acute aerobic 
exercise using microarray technology 
1) Subject recruitment is ongoing. 
2) Expansion of the study to include the investigation of skeletal muscle is in 
progress. 
3) Depending on future funding, the study will expand to include the 
investigation of females. 
4) Depending on future funding, the study will expand to include the 
investigation of different age ranges. 
5) Functional studies using protein microarrays are planned in the future with the 
collaboration of other researchers. 
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Appendix 1 
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Figure A-1 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from lean subject 1 (pre-exercise). 
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Figure A-2 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from lean subject 1 (post exercise). 
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Figure A-3 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from lean subject 2 (pre-exercise). 
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Figure A-4 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from lean subject 2 (post exercise). 
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Figure A-5 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from lean subject 3 (pre-exercise). 
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Figure A-6 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from lean subject 3 (post exercise). 
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Figure A-7 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from lean subject 4 (pre-exercise). 
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Figure A-8 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from lean subject 4 (post exercise). 
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Figure A-9 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from lean subject 5 (pre-exercise). 
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Figure A-10 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from lean subject 5 (post exercise)_ 
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Figure A-ll The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from obese subject 1 (pre-exercise). 
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Figure A-12 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from obese subject 1 (post exercise). 
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Figure A-13 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from obese subject 2 (pre-exercise). 
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Figure A-14 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from obese subject 2 (post exercise). 
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Figure A-15 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from obese subject 3 (pre-exercise). 
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Figure A-16 The electropherogram oftotal RNA of abdominal subcutaneous adipose 
tissue from obese subject 3 (post exercise). 
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Figure A-17 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from obese subject 4 (pre-exercise). 
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Figure A-18 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from obese subject 4 (post exercise). 
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Figure A-19 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from obese subject 5 (pre-exercise). 
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Figure A-20 The electropherogram of total RNA of abdominal subcutaneous adipose 
tissue from obese subject 5 (post exercise). 
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Figure A-21 The electropherogram of Universal Human Reference RNA. 
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